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Summary 
A remarkable feature of cancer-associated Human papillomavirus (HPV) types (e.g. 
HPV16/18) is that the open reading frame (ORF) of the major capsid protein L1 comprises 
alternative translation initiation codons, thereby potentially encoding different isoforms. Notably, 
the same can be found within the genome of Mastomys natalensis papillomavirus (MnPV), an 
etiological agent for non-melanoma skin cancer in the rodent Mastomys coucha.  
 
Capsid formation of these L1 variants was tested using both baculovirus and pseudovirus 
production systems. L1 translated from the first and second ATG (referred as L1LONG and L1MIDDLE) 
inefficiently induced capsid formation. In contrast, virions could be efficiently formed with 
capsomeres derived from L1SHORT protein starting from the third ATG. Even after adding L1SHORT 
and L2 proteins, L1LONG and L1MIDDLE were still unable to form the spherically correct virus 
particles. 
 
Analysis of MnPV-infected animals during early infection revealed strong serological 
responses against MnPV L1LONG and L1MIDDLE protein, but these antibodies were not protective. 
Contrary, neutralizing antibodies against conformational epitopes of L1SHORT only appeared during 
the late phase of infection, apparently enabling the virus to accumulate. Therefore, the additional 
N-terminal part of L1LONG might play a decisive role in capsid formation and form a loop which 
prevents the assembly of correct capsomeres in vivo. Such a transitory conformational epitope is 
apparently only recognized during early infection, allowing the virus to escape from humoral 
immune surveillance. Moreover, using competition assays during pseudoviruses formation 
revealed that L1LONG protein could interfere with the capsid forming process in the presence of 
L1SHORT. This could be also shown by changes in intracellular localization when L1LONG or L1MIDDLE 
is co-expressed with L1SHORT.  
 
In summary, these data provide evidence of an adaptive immune escape initial after 
infection by avoiding the production of protective antibodies. Since other “high-risk” mucosal and 
cutaneous HPVs can also encode such L1 isoforms, these results may have important implications 
in the establishment of a persistent viral infection and the outcome of the disease. 
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Zusammenfassung 
Eine bedeutsame Eigenschaft krebsassoziierter humaner Papillomavirus (HPV)-Typen (z.B. 
HPV16/18) ist es, dass der offene Leserahmen (ORF) des Hauptkapsidproteins L1 mehrere 
alternative Translationsinitiationscodons enthält. Somit können potentiell verschiedene L1 
Isoformen synthetisiert werden. Dieselbe Konstellation findet man auch im Genom des Mastomys 
natalensis papillomavirus (MnPV), dem ätiologischen Agens für die Entstehung von nicht-
melanozytären Hautkrebs im Nagetier Mastomys coucha. 
 
Die Rolle dieser L1-Varianten bei der Bildung intakter Kapside wurde sowohl in einem 
Baculovirus- als auch in einem Pseudovirus-Produktionssystem getestet. L1 Varianten welche ab 
dem ersten bzw. zweiten ATG Startcodon translatiert werden (als L1LONG und L1MIDDLE bezeichnet) 
bilden nur sehr ineffizient virale Kapside aus. Im Gegensatz dazu können Kapsomere mit dem 
dritten ATG beginnenden L1SHORT-Proteins sehr effizient infektiöse Partikel ausbilden. Auch nach 
Zugabe von L1SHORT- und L2- Proteinen sind L1LONG und L1MIDDLE nicht in der Lage korrekte 
Viruspartikel zu bilden. 
 
Biologisch relevant sind diese Ergebnisse deshalb, da die Analyse von MnPV-infizierten 
Tieren während frühen Phasen der Infektion ergab, dass trotz starker serologischer Reaktion 
gegen L1LONG und L1MIDDLE Proteine keine neutralisierende Antikörper gebildet werden. Diese 
werden nur im späteren Infektionszyklus gegen Konformationsepitope von L1SHORT gebildet und 
erlaubt daher den Viren sich in der frühen Phase zu vermehren. Dabei spielt der zusätzliche N-
terminale Teil von L1LONG eine entscheidende Rolle da sich dadurch die Konformation ändert 
welche die Bildung von korrekten Kapsomeren in vivo verhindert. Ein solches 
Konformationsepitop wird offenbar nur während einer frühen Infektionsphase synthetisiert, 
sodass das Virus der humoralen Immunantwort entgeht. Darüber hinaus zeigten 
Kompetitionsassays, dass das L1LONG-Protein das „Assembly“ zu intakten Kapsiden in Gegenwart 
von L1SHORT stört. Dies konnte auch durch Veränderungen in der intrazellulären Lokalisation 
gezeigt werden, wenn L1LONG oder L1MIDDLE mit L1SHORT co-exprimiert wurden. 
 
Zusammenfassend zeigen diese Daten, dass MnPV durch die Synthese unterschiedlicher 
L1 Isoformen die adaptive Immunantwort umgeht indem es die Produktion von protektiven 
Antikörpern in der frühen Infektionsphase verhindert. Da auch andere "risikoreiche" mukosale 
und kutane HPVs solche L1-Isoformen kodieren können, könnten ähnliche Mechanismen 
vorliegen was virale Persistenz und damit die Entstehung von Tumoren begünstigt. 
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1. Introduction 
1.1 Papillomaviruses 
Papillomaviruses (PVs) are a diverse cluster of small non-enveloped DNA viruses that 
infect a range of different species including reptiles, birds, marsupials, and mammals [1]. Up to 
date more than 300 papillomaviruses types were identified including 210 human papillomaviruses 
(HPVs) as well as 170 animal papillomaviruses (PaVE: Papillomavirus Episteme) [2]. They are 
divided into different genera based on the nucleotide sequence comparison (at least 10 percent 
difference), which are named with Greek letter: alpha, beta, gamma, mu and nu for HPV and pi, 
omicron, xi, lambda, kappa, iota, theta, eta, zeta, epsilon and delta etc. for animal papillomaviruses 
[3, 4].   
 
Figure 1.1: Papillomavirus phylogenetic tree [5]. E1, E2, L1 and L2 genes from 241 papillomaviruses were 
downloaded from PaVE and aligned for construction of the phylogenetic tree. The colors represent presence 
or absence of adaptive proteins. Red clades lack an E6 ORF, green clades lack E7 protein and purple clades 
lack E5 gene. Mastomys natalensis papillomavirus (MnPV) belongs to iota-papillomavirus family and 
Mastomys coucha papillomavirus 2 (McPV2) is classified to pi-papillomavirus family. 
 
1.2 Human papillomaviruses 
In general, HPV infections can be potentially cleared by immune system. However, for 
some instances, HPVs can cause benign hyper-proliferative lesions such as warts or asymptomatic 
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lesions at particular anatomic sites, which in some cases can progress to invasive malignant cancer 
[6]. The cutaneous HPVs facilitate benign papillomas in the skin, of which most manifestations are 
common plantar and flat warts [7]. The genital HPVs, which are responsible for benign warts or 
malignancies in penile, vulvar and anal, are considered to be the causative agents of most cervical 
cancers [8]. According to clinical pathologies, HPVs are classified into ‘‘low risk’’ cutaneous type 
(e.g. HPV 3, HPV 10 and HPV61 etc.); ‘‘low risk’’ mucosal type (e.g. HPV 6, HPV11 and HPV 13 
etc.) and ‘‘high risk’’ type (e.g. HPV 16, HPV 18 and HPV 45 etc.). On the basis of epidemiological 
data, HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 59, 69, 73 and 82 are confirmed as ‘‘ human 
carcinogens ’’, which are responsible for 99.7% cervical cancer [9, 10]. Especially, HPV 16 and 
HPV 18 are the most prevalent pathogens causing 50% and 20% of all cervical cancer cases. 
Cervical cancer, a major burden worldwide, is the fourth most frequent cancer in women causing 
528,000 cases and 266,000 deaths every year [10]. In a small group of infected women, continuous 
infection leads to low or high grade cervical interepithelial neoplasia (CIN), and eventually results 
in invasive cancer, where the viral genome integrate into the host genome [11]. The virus-like-
particle (VLPs) based vaccines e.g. Cervarix (HPV16 and 18), Gardasil (HPV 6, 18, 11 and 16) and 
Gardasil-9 (additionally HPV 6, 18, 11, 16, 31, 33, 45, 52 and 58) are the current strategy to 
prevent cervical cancer. 
 
1.3 The papillomaviruses genome  
Papillomaviruses have a double stranded circular DNA genome, which ranges from 6953 
bp [Chelonia mydas papillomavirus type 1 (CmPV1)] to 8607 bp [Canine papillomavirus type 1 
(CPV1)] in length [5]. The genome is normally associated with the cellular histones [12] and 
contains three regions: the upstream regulatory region (URR), the early region and the late region. 
The URR encompasses several cis-regulatory elements including early promoter, viral origin of 
replication and various transcriptional regulatory sites for cellular and viral transcription factors.   
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Figure 1.3: The typical mucosal high-risk HPV genome [13]. The HPV 16 genome with a size of 8 kb contains 
early region (E1, E2, E4, E5, E6 and E7), late region (L1 and L2) and the upstream regulatory region (URR). 
The early genes E1 and E2 play a role in the viral replication and transcription, whereas E6 and E7 
oncogenes are essential for transformation. The late region encodes viral structural L1 and L2 proteins, 
which modulate capsid assembly and encapsidation of viral genome. The URR harbors cis-regulatory 
elements such as promoter, replication origin and transcription factor binding sites. AL: polyA (late); AE:  
polyA (early). 
 
The early region contains five to six open reading frames (ORFs): E1, E2, E4, E5, E6 and E7, 
while the cutaneous PV types typically miss E5 gene [14]. The replication origin is comprised of a 
palindromic E1 binding region, two to three E2 binding sites and an A/T rich region [15-17]. The 
hexameric DNA helicase E1 is thought to be an essential protein for initiation and catalysis of viral 
DNA synthesis in the nucleus of infected keratinocytes. E1 unwinds DNA at the origin ahead of 
replication fork and mediates with cellular DNA replication factors by assembly into its 
enzymatically active form - a double hexamer [18]. For most PV types, E2 acts as a molecular 
enhancer to initiate DNA replication by directing E1 helicase onto the origin [19, 20]. E2 can 
engage in the binding to the sequence motifs in the viral genome, which can activate or repress 
the transcription. E2 represses the transcription by the competition with a short form of E2 for 
binding to binding sites or recruitment of repressor complexes to viral DNA [21-23]. E4 gene is 
entirely located within the E2 ORF, which is often expressed from a spliced mRNA and present as 
E1∧E4 transcript. Despite E4 protein is expressed before the late genes, it always serves as a 
biomarker of active virus infection due to its frequency expression at the late stages of the viral life 
cycle, around the time that genome amplification is initiated. E1∧E4 protein mainly contributes to 
the virus release and transmission by its disruption of cellular keratin network and formation of 
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the cornified envelope [24, 25]. The transmembrane E5 protein engages in multiple interactions 
with cellular growth receptors such as PDGF β receptor and EGF receptor, thus facilitating 
transformation and the development of carcinomas [26]. The oncoproteins E6 and E7, which 
induce the degradation of the host cell tumor suppressors p53 and retinoblastoma (Rb) protein, are 
the primary reason for tumorigenesis [8]. These two factors act cooperatively in the development 
of HPV-induced cancers. As the key regulators of S phase genes, Rb protein controls the activity 
of E2F transcription factors [27]. Thus, the efficient binding of Rb and E7 could promote 
premature S phase entry and DNA synthesis, leading to inhibited cell growth and apoptosis, as 
well as driving productive viral life cycle for tumor progression [28]. However, the block of Rb 
function by E7 results in increased levels of p53, and E6 correspondingly disrupts p53 for 
degradation allowing avoidance of apoptosis [29]. This gives rise to the accumulation of DNA 
damage and mutations that can promote transformation and carcinogenesis. 
 
1.4 The open reading frame of L1  
The L1 gene expression is restricted to the late phase of the viral life cycle, which occurs in 
the differentiated keratinocytes in the Stratum granulosum [30]. L1 transcripts are generated from 
the polycistronic mRNA isoforms under the control of URR and generally mediated by the late 
promoter within E7 gene. During the late gene expression, the early gene mRNAs are removed by 
viral RNA splicing when the transcriptional machinery passes through the early region and fails to 
recognize the early polyadenylation signal [31].  
 
For many PV types, especially the high-risk HPVs, L1 protein contains several alternative 
translation initiation codons, which can potentially synthesize several isoforms of L1. Many well-
established cervical carcinomas associated types, such as HPV16, 18, 45, 52, 54 and 58, contain the 
additional ATGs. However, the alternative upstream ATG is absent in “low-risk” types linked with 
genital warts such as HPV 6b, 11, 13, 42, 44 and 55, as well as HPV 3, 7, 9, 10, 12, 36 and 37 which 
associate with benign lesions [32]. Therefore, it is attempted to speculate that the capability to 
synthesize different isoforms of L1 protein might contribute to the development of carcinomas. 
The alignment of L1 proteins from different PV types indicates that there is a consensus 
MxxWx7YLPP motif at N-terminal region. It is reported that virus-like particles (VLPs) can only 
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be efficiently assembled from the short L1 version of which the methionine is close to this 
Wx7YLPP motif [33].  
 
Figure 1.4: The alignment of L1 sequence (adapted from Dr. Sabrina Vinzón, modified according to [33]). L1 
proteins N-terminus sequences from 28 PV types were aligned by the Clustal Omega online. The red boxes 
indicate the highly conserved sequences (MxxWx7YLPP) at the N-terminus of L1 sequence. The different 
genera of the PVs are marked. Both MnPV and McPV2 contain three translation initiation codons at the N-
terminal sequences of L1. 
 
1.5 The L1 monomer structure 
The L1 monomer contains a canonical ‘‘jelly roll’’ β sandwich (eight-strand β barrel: BIDG-
CHEF), five α helices (h1 - h5) and six loops (BC, CD, DE, EF, FG, and HI), five of which (besides 
CD) are the surface loops of capsomere [34]. Eight antiparallel stranded β jellyrolls form the core 
structure of L1, with the strands linked with loops on the top of pentamer knob, where the most 
neutralizing antibodies bind. There are several interpentameric and intrapentameric disulfide 
bonds between the neighboring subunits, which play an important role in the interaction with 
pentamers within the particles, thus facilitating capsid stability. For example, the HI surface loop 
from one monomer intertwines with the neighboring anticlockwise FG and EF loops. The helices 
h2 and h3 form a V-shape groove, which has a hydrophobic interface with the neighbor monomer 
h4. The G1 segment strand of the BIDG β barrel from one L1 monomer connects with the 
neighboring monomer CHEF β sheet. The N-terminal and C-terminal domain of L1, as the 
‘‘invading arm’’, form the interpentameric contacts by invading the arms to the adjacent 
pentamers [35, 36]. The residues 1-20 of the N-terminal arm are conserved in all papillomaviruses 
and are thought to fill the gap in the virions shell, which is essential for maintaining the capsid 
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stability [35]. The deletions of up to 30 residues of the C-terminus as well as the addition 
sequences to C-terminus do not interrupt the pentamer structure [37-39]. The residues at C-
terminus (approximately after residue 474) return to the L1 pentamer origin. Two conserved 
cysteines Cys175 and Cys428 are involved in the intercapsomeric disulfide bridge, which facilitate 
the formation of intact virus capsid [31, 34]. 
 
Figure 1.5: The HPV16 L1 monomer with residues from 20 to 474 [36]. The β ‘‘jelly roll’’ strands and h1 helix 
are in blue. The helices h2 - h5 and βJ strand are marked in yellow. The G1 strand segment is in red. The F 
strand of the clockwise neighbor is in green. The six BC, CD, DE, EF, FG, and HI loops are in pink. 
 
1.6 The papillomaviruses capsid 
Papillomavirus capsid is a 50-60nm in diameter icosahedral particle that is composed of 
multiple copies of major capsid protein L1 and minor capsid protein L2 [40]. The major capsid 
protein L1, with molecular mass of around 55 kDa, could spontaneously self-assemble into virus 
like particles (VLPs) [41], without viral DNA encapsidation. These VLPs can be produced in insect 
cells by the baculovirus expression system and in yeast, which result in particles presenting an 
exterior surface virtually indistinguishable from native virions [41-43]. Five copies of L1 monomer 
spontaneously self-assemble into the pentameric capsomere, which presents mushroom-like 
protrusions (11-12nm in diameter) along with five-points star-shaped heads [44]. Seventy-two 
capsomeres with small amounts of L2 proteins in the proximal pocket form infectious virus 
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particles with the icosahedral lattice symmetry T = 7. Even though it is not necessary to form 
VLPs with the participation of L2 proteins, it is reported that twelve L2 proteins are incorporated 
into native viral capsid by the hydrophobic C-terminal arm [45]. However, the abundance of L2 
within capsid can be arranged up to 72 molecules, which presents an icosahedral L2 density 
beneath the axial lumen per L1 capsomere [46]. The internal diameter of the viral capsid shell is 
around 42 - 46nm [34, 44]. Twelve pentavalent pentamers, each surrounded by five other 
pentamers, are centered on 5-fold symmetry axes. However, 60 hexavalent pentamers, each of 
which is surrounded with six other capsomeres, are centered at 6-coordinated positions [44] [47]. 
Therefore, each hexavalent lattice point is encompassed by five hexavalent points and one 
pentavalent point. A twelve pentameric icosahedral particle (T = 1, small VLP) was formed by N-
terminus truncated L1 proteins, indicating that N-terminal polypeptides (1-20 residues) might 
play an important role in the intercapsomeric contacts by blocking the C-terminal arm from 
returning to pentamer of origin [36].  
 
Figure 1.6.1: The papillomavirus capsid structure [35, 47]. The papillomavirus capsid consists of major capsid 
protein L1 and minor capsid protein L2. The N-terminal truncated L1 proteins (ΔN-10) form a small 12 - 
pentamer icosahedral particle (T = 1). 360 copies of L1 with twelve L2 form a T = 7 papillomavirus capsid. 
Each hexagon is surrounded by five hexagons and one pentagon.  
 
For a T = 7 lattice, there is a left T = 7 laevo or a right T = 7 dextro handed enantiomorph. 
However, it is assumed that particle structures only have the same hand among the viral capsids 
within a particular virus strain. For example, apart from cottontail rabbit papillomavirus (CRPV), 
which is the only T = 7 laevo capsid, other papovaviruses, such as simian virus 40, murine 
polyomavirus and human papillomavirus, are all T = 7 dextro icosahedral particles. The 
triangulation number of papillomavirus particle (T = 7) is defined by the arrangement of lattice 
points between adjacent pentavalent points. A T = 7 lattice exhibits a “two steps (h) starting from a 
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pentavalent point forward onto two neighboring hexagons followed by one step (k) to the left or 
right pentavalent point” pattern. Therefore, the triangulation number of icosahedron is calculated 
by the formula: T = h2 + hk + k2 [44].   
 
Figure 1.6.2: Calculation of the triangulation number [44]. There are two icosahedral lattices with a 
triangulation number of seven: left T = 7 laevo and right T = 7 dextro handed enantiomorph. The particle is 
formed by sixty hexavalent and twelve pentavalent capsomeres. The calculation figure is adapted from the 
ViralZone website. 
 
1.7 Capsid assembly 
The major capsid proteins L1 are expressed and assembled into capsomeres in the 
cytoplasm of terminally differentiated keratinocytes. Subsequently, the assembled capsomeres pass 
through the nuclear pores and are translocated into nucleus due to the nuclear localization 
sequence (NLS) signal at C-terminus of L1 protein [48, 49]. The minor capsid proteins L2 normally 
associate with promyelocytic leukemia protein (PML) bodies and translocate into nucleus, thus 
assisting capsid assembly [50]. It is reported that L2 could facilitate the transport of L1 capsomeres 
to nucleus, and complement L1 nuclear translocation even NLS of L1 is defective [51]. The viral 
capsid assembly machinery eventually occurs in the nucleus based on the translocation of L1 and 
L2 proteins after packaging with the replicated PV genomes. Both L1 and L2 proteins are able to 
bind DNA without sequence specific interaction in vitro, suggesting that they might directly bind 
virus genomic DNA, thus enabling DNA encapsidation [52, 53]. The positively charged residues 
from C-terminal region of L1 (also overlapping with the NLS) and both N-terminus and C-
terminus of L2 are the potential DNA-binding domains. However, even though eight residues 
from N-terminus or nine C-terminal amino acids of L2 are deleted, viral genome encapsidation 
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still remains, but resulting in non-infectious virions [54, 55]. L2 could also recruit E2 to PML 
bodies, suggesting a role of E2-mediated replication during DNA encapsidation process [56]. The 
participation of L2 in capsid assembly might influence the final structure of virions and 
additionally increase viral infectivity and virus nucleic acid encapsidation. 
 
Depending on the L1 proteins self-assembly ability, VLPs, pseudoviruses (PsVs) and 
quasivirions (QV) are produced in different synthetic systems in vitro, which could mimic the 
structure of the native viral capsid (T = 7 icosahedral lattice). VLPs can be produced in different 
prokaryotic or eukaryotic systems such as mammalian cells, Sf9 cells, E.coli, or yeast by 
transfection of expression plasmids containing L1 alone or L1 with L2 together [41, 42, 57]. Since 
VLPs are found to be uniform in size and remain similar structures as the native virions, vaccines 
based on VLPs production are used to induce high titer of neutralizing antibodies to prevent HPV 
infection [58]. PsVs are produced by transfection of L1 and L2 codon-modified expression 
plasmids as well as a reporter plasmid containing GFP/Gaussia luciferase with a size of 5.9 kb. 
Since the expression of wild type L1 and L2 genes is restricted in cultured mammalian cells, L1 
and L2 ORFs are codon modified [59]. The primary amino acid sequence is not changed but a 
significantly increased expression can be achieved by these codons changes.  The plasmid 
containing SV40 origin of replication (ori) is used for generation of high copy number 
pseudogenomes, which can be packaged in the capsids. 293T or 293TT cells that express high 
levels of SV40 large T antigen (LT) enable the replication of plasmids containing SV40 ori. After 
maturation, PsVs are isolated from cell debris in detergent and high salt solution, and then 
followed by Optiprep ultracentrifugation. The Optiprep gradient, which presents a combined 
velocity sedimentation and buoyant density, is much more efficient for virus purification than the 
classic CsCl purification [60]. QV production in 293T or 293TT is a similar technology to that of 
PsVs. The only difference between QV and PsVs production is that re-circularized HPV genomes 
rather than reporter plasmids are incorporated into particles. The PsVs and QV production can be 
used in multiple aspects including particles structure, capsid assembly, neutralization capacity and 
virus entry [61].  
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Figure 1.7: Schematic overview of VLP, PsVs and QV production [61]. The synthetic papillomavirus particles 
(SPP) are produced by transfection of plasmids expressing capsid proteins L1 alone, or together with L2. The 
difference of three particles production is the presence or absence of incorporated DNA. PsVs contain 
reporter plasmids with GFP/Gaussia luciferase and QV contain full length papillomavirus genomes.  
 
VLPs can be disassembled into capsomeres in the presence of reducing agents, such as 
dithiothreitol (DTT), with low ionic strength and high pH (pH = 8.2) [62] [63]. This is caused by 
the insufficient formation of disulfide bonds network within pentamers under the reducing 
condition. However, instead of particles disassembly, DTT treatment to BPV purified intact 
particles leads to a conformational change (expansion of 10% in diameter), and finally results in 
virions disruption by the entry of proteases and nucleases to the interior [64]. Therefore, for virus 
particles production, there are several methods to stabilize the intact structure, such as high ionic 
strength (> 0.5 M sodium chloride), low pH and removal of reducing agents. The reassembly of 
VLPs can be achieved by simply dialyzing out the disassembly buffer.  
 
1.8 The human papillomaviruses life cycle 
HPVs infection as well as the viral gene expression is absolutely confined to the 
keratinocyte differentiation program, which presents in a differential spatial and temporal pattern 
[13]. The initial HPV infection occurs in keratinocytes in the basal layer of epithelium due to 
abrasion or micro-wounds during scarification or sexual intercourse [65]. The virus attachment to 
the host cells mainly depends on the binding of heparin sulfate proteoglycans (HPSGs) on the cell 
surface with C-terminus of L1 protein, thus leading to the conformational change of L1 and 
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subsequently exposure of N-terminal domain of L2 [65-67]. The L2 additional epitopes are then 
exposed by furin protein convertase cleavage at amino acid 12, which is important for the 
internalization of virus capsids into cells and transport of virus genomes to nucleus [66, 68]. After 
virus binding and entry, the viral genomes are established in the nucleus as low-copy episomes 
(20-100 per cell) and replicated in synchrony with the expression of the early genes E1 and E2 
[69-71]. The infected cells undergo differentiation and the cellular DNA synthesis machinery 
enables viruses to maintain the productive phase of the viral life cycle. After cell division, the 
infected daughter cell migrates away from the basal layer and enters the spinous layer. The 
expression of E6 and E7 pushes differentiating infected cells into S phase, resulting in the 
immortalization of the host cells and facilitating the following steps for tumorigenesis [72, 73]. A 
dramatically amplification of viral DNA (many thousands of viral copies per cell) and gene 
expression is achieved in this stage, along with activation of the late viral promoter [74, 75]. 
Finally, L1 and L2 proteins in the late phase assemble into infectious particles encapsidated with 
synthesized viral genomic DNA, which are then released from the uppermost layers (Stratum 
granulosum) [76]. 
 
Figure 1.8: The PV life cycle in the infected epithelial tissue [13]. The HPV infectious life cycle is tightly 
restricted to the infected epithelium differentiation and divided into early and late phase. The virus infects 
keratinocyte in the basal layer through micro-wounds. The expression of E1 and E2 proteins mediates the 
replication of the viral genome, which coincides with the cell division. During the program of 
differentiation, the early genes E6 and E7 expression is strictly controlled, unless the infected cells terminate 
division and start differentiating into mature status. This leads to a highly amplification of viral gene 
expression and genome cope numbers. Finally, L1 and L2 proteins in the top layer assemble into infectious 
particles with replicated viral genome, which are then released from the tissue through desquamation 
process.  
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1.9 The humoral immune response against papillomaviruses 
The humoral immune responses against papillomaviruses antigens are used to monitor the 
course of infection. There are different antibodies responses, which mainly are against early 
proteins E2, E4, E6 and E7 as well as the viral capsid proteins L1 and L2. E2 seroresponses are 
more abundant in CIN1-2 lesions and decrease within the higher grade CIN as well as cervical 
cancer population. Anti-E4 antibodies are more frequently present in the population with 
precancerous lesions than the healthy group or the one with cervical cancer. [77]. The humoral 
responses to E6 and E7 are found to correlate with cervical cancer and pre-cancer lesions [78, 79]. 
Compared to E6, there is a higher rate for a correlation of E7 antibodies responses with the late 
stage cervical cancer [80, 81]. However, some reports suggest that E7 seroresponses are associated 
with the early stage of cervical cancer such as CIN3 lesions [82].  
 
The HPV serotype specific L1 responses are generally detected in individuals with long 
term viral infection and HPV-carrying high grade CIN [83, 84]. However, these responses are 
developed very slow and finally detectable around 8 and 9 months after the first HPV positive 
DNA detection. Two L1 peptides located on the L1 surface exposed regions are strongly positive in 
the cervical cancer patients’ sera [85]. VLPs are used to measure the neutralizing antibodies 
responses as well as some conformational epitopes. The antibodies against VLPs are increased with 
the grade of cervical lesions [77]. Based on previous results, L1 positivity against MnPV is a 
potential serological marker for tumor development, whereas E2 seroreactivity can be used as an 
early marker for virus infection [86] .  
 
Figure 1.9: Anti-E4, E6, E7 and L1 antibodies responses in different populations with different CIN grade and 
cervical cancer [77]. CC: Cervical cancer 
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1.10 Animal models for papillomaviruses research 
Various animal models are used to comprehensively understand HPV infection in human 
including virus life cycle, immune responses and process of lesion formation. The earliest models 
of PV study are cottontail rabbit papillomavirus (CRPV) and bovine papillomavirus type 1 (BPV1), 
but neither of them are the ideal models [87]. In 1933, CRPV was found as a transmissible agent 
for the prominent papillomas formation in cottontail rabbits and domestic rabbits at the cutaneous 
sites [88]. However, as CRPV natural host, cottontail rabbits are not easy to be kept in captivity 
since they are genetically diverse wild animals. Therefore, the use of DNA gun technologies allows 
experimental infection of CRPV to the domestic rabbits, thus investigating the individual roles of 
viral proteins during the process of tumorigenesis. In addition, CRPV is also used for the 
preclinical trials of prophylactic vaccines. However, compared to the high abundance of virus 
production in cottontail rabbit’s lesions, there are few or no infectious virions in domestic rabbits 
leading to an incomplete virus life cycle [87].  
 
Six BPVs can be divided into two groups according to the ability to induce fibropapillomas 
(BPV1 and 2) or papillomas (BPV 3, 4 and 6). BPV5 is the unique one that can induce both 
fibropapillomas and papillomas. BPV1 causes fibropapillomas of teats, udders and penis of cows. 
BPV2 induces fibromas and polyps of skin, squamous cell carcinoma of the gastrointestinal tract 
and bladder cancer. In cattle, BPV 1 and BPV 2 are the only papillomaviruses that can infect other 
hosts including horses, donkeys and mules. BPV4 intensifies the carcinogenic process at the upper 
gastrointestinal (GI) tract under the presence of immunosuppressant and chemical carcinogens in 
bracken fern fed cattle. BPV6 infection at teats and udders is not only a healthy burden but also an 
economic issue [89]. However, even though BPVs cause diverse lesions in their natural hosts, cows 
are inconvenient animal models to study the PV-associated diseases due to their size and cost [87].  
 
Furthermore, canine oral papillomavirus (COPV/CPV1), which induces oral papillomas in 
dogs, is used for the preclinical vaccination study. Recently, COPV is replaced by the rabbi oral 
papillomavirus (ROPV) [90-92]. By using these models, it is shown that vaccination of VLPs can 
elicit neutralizing antibodies to protect individuals from PVs infection as well as experimentally 
induced tumors [93]. Another animal papillomavirus type named Mus musculus papillomavirus 
(MmuPV), which induces papillomas in the immunosuppressed mice, is the closest model for 
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studying β-PVs infection. Besides, MmuPV can also infect the mucosal genital tissues, which is 
also observed in beta and gamma HPVs infection. Therefore,  MmuPV as a model to resemble β- 
and γ-PVs, can potentially provide information regarding the pathogenic mechanism [87].   
 
The African multi-mammate mice Mastomys coucha, which belongs to the rodent family 
Muridae, is a promising model to investigate the principle of PV-associated skin tumorigenesis at 
DKFZ [94, 95]. They are naturally infected with Mastomys natalensis papillomavirus (MnPV) and 
Mastomys coucha papillomavirus 2 (McPV2), which infect epidermal and mucosal tissues, 
respectively [95, 96]. MnPV belongs to iota-papillomavirus family and McPV2 is classified to pi-
papillomavirus family. The reason why the names of two viruses are different is due to the fact 
that these animals were considered as Mastomys natalensis by mistake for a long time, until a 
taxonomical re-classification as Mastomys coucha was achieved [94, 97-99]. Although both species 
have similar morphology, the chromosome set is totally different, which is 32 chromosomes for 
Mastomys natalensis and 36 chromosomes for Mastomys coucha. There is no evidence of DNA 
integration in the host genome for these two papillomaviruses. The viral genomes persist in the 
episomal status in Mastomys, which is analogous to cutaneous HPVs types [100]. MnPV and 
McPV2 are not transmitted in utero and natural infection occurs earlier than eight weeks after 
birth [101]. The infection of viruses elicits diverse immune responses against the viral proteins. A 
high incidence of naturally developing skin and anogenital lesions can be found in the majority of 
older animals, including papillomas, keratoacanthomas and condylomas [96] [102, 103].  
 
The virus-free colony was established by hysterectomies on pregnant Mastomys under 
sterile conditions. The offspring were nursed by mice which were kept in specified pathogen-free 
(SPF) isolator system. The antibodies responses against MnPV and McPV2 together with the viral 
DNA is regularly tested to verify the pathogen free. The virus-free animals can be used as a control 
in the vaccination study or UV irradiation. Especially, experimental infection can be performed on 
these animals for certain purposes. By using Mastomys model, it is reported that immunization of 
VLPs can raise long-lasting neutralizing antibodies responses that completely prevent the 
appearance of skin tumors under immunocompetent and immunosuppressed conditions [100]. 
Mastomys coucha can also be a suitable model for non-melanoma skin cancer (NMSC) 
development along with MnPV infection and UV exposure, which reflects a similar situation in 
human [104]. Therefore, Mastomys coucha performs an ideal model to exhibit an analogous 
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tropism and pathogenicity as skin-associated HPV under different conditions, such as 
immunization, immunosuppression and UV irradiation. 
 
Figure 1.10: Mastomys coucha. The infection of MnPV leads to skin papillomas (A) in the older populations 
of Mastomys. The McPV2 infection leads to the mucosal tumors such as Oral papillomas (B) and condylomas 
(C). (D). The MnPV and McPV2 genome. Both genomes are approximately 7,600 bp and lack E5 open 
reading frame. 
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1.11 Aim of the study 
HPVs have developed a variety of strategies to evade clearance by innate and adaptive 
immunity [105, 106]. A common feature of high-risk HPV types is that the open reading frame of 
the major capsid protein L1 contains alternative translation initiation codons. A VLP-based 
vaccine derived from L1 protein is crucial for the prevention of virus infection, since VLPs can 
resemble the structures of native virions and are able to elicit neutralizing antibodies. Therefore, it 
is worthy investigating the capsid formation ability of different L1 isoforms and the role in virus 
infection, especially the immune escape mechanism. In this context, since three start codons of L1 
protein are found in MnPV genome, which initiate L1LONG, L1MIDDLE and L1SHORT, respectively, 
Mastomys exhibits as an optimal model. The animals are naturally infected with MnPV, providing 
an analogous tropism and pathogenicity as wart-associated HPV. The major aims of this study are: 
 
1) The capsid formation ability of different L1LONG, L1MIDDLE and L1SHORT proteins.  
⚫ VLPs production by Baculovirus expression system 
⚫ Production of pseudoviruses 
 
2) The characterization of anti-L1LONG, L1MIDDLE and L1SHORT antibodies in the naturally MnPV-
infected animals. 
⚫ Follow up of anti-L1 antibodies at different time points 
 
3) Neutralizing capacity of anti-L1LONG, L1MIDDLE and L1SHORT antibodies 
⚫ Neutralizing assay 
 
4) Epitope identification of anti-L1LONG, L1MIDDLE and L1SHORT antibodies 
⚫ Denatured-VLP ELISA and Denatured-GST ELISA of anti-L1 antibodies at different time 
points 
⚫ Epitope mapping 
 
5) Interaction between L1LONG and L1SHORT proteins 
⚫ Comparison of pseudovirus infectivity between “L1S + L2” and “L1L + L1S + L2” group 
⚫ Colocalization of L1LONG, L1MIDDLE and L1SHORT proteins in the transfected HeLa cells. 
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2. Material 
2.1 Chemicals and reagents 
Acetic acid  Merck Calbiochem, Darmstadt  
Acrylamide-Bis Solution (29:1), 30% w/v  Serva Feinbiochemica, Heidelberg  
Agarose  Sigma-Aldrich, Steinheim  
Ammonium persulfate  Sigma-Aldrich, Steinheim  
Aqua ad iniectabilia Braun, Melsungen 
Bradford-Reagent  Bio-Rad Laboratories, München  
10% Briji 58  Sigma-Aldrich, Steinheim 
Bromphenol blue Serva Feinbiochemica, Heidelberg 
BSA Molecular Biology Grade (20 mg/ml)  New England BioLabs, Frankfurt/Main  
Casein from bovine milk  Sigma-Aldrich, Steinheim  
CaCl2 Sigma-Aldrich, Steinheim  
Chloroform Merck Calbiochem, Darmstadt 
Complete Protease Inhibitor Cocktail Roche Diagnostics, Mannheim 
CsCl Roth, Karlsruhe 
Dako Faramount Aqueous Mounting Medium  Dako Deutschland GmbH, Hamburg  
DAPI Sigma-Aldrich, Steinheim 
DTT Biomol, Hamburg 
dNTPs Set PCR Grade  Thermo Fisher Scientific, Darmstadt  
EB buffer  Qiagen, Hilden  
ECL SuperSignal West Femto Thermo Scientific, St. Leon-Rot 
EDTA  Carl Roth GmbH, Karlsruhe  
Enhanced Chemiluminescence Substrate (ECL)  PerkinElmer, USA  
Ethanol, absolute  Merck Calbiochem, Darmstadt  
Ethidium bromide, 1% solution  Sigma-Aldrich, Steinheim  
Formaldehyde Merck Calbiochem, Darmstadt 
Gaussia-Juice BIG KIT  jpk GmbH, Kleinblittersdorf  
Glucose Roth, Karlsruhe 
Glycerol  AppliChem, Darmstadt  
Glycine  Gerbu, Gaibach  
H2O2 Merck Calbiochem, Darmstadt 
HEPES Eurobio Les Ulis Cedex, France 
IsoFlo 100% v/v inhalation gas, liquid Toetis Ö sterreich GmbH, Wien 
KCl  Merck Calbiochem, Darmstadt  
KH2PO4  Carl Roth GmbH, Karlsruhe  
L-Glutathione reduced Sigma-Aldrich, Steinheim 
Methanol Sigma-Aldrich, Steinheim 
MgCl2 Merck Calbiochem, Darmstadt 
MgSO4 Sigma-Aldrich, Steinheim 
Milk powder Carl Roth GmbH, Karlsruhe 
NaCl Carl Roth GmbH, Karlsruhe 
Na2CO3 Carl Roth GmbH, Karlsruhe 
NaHCO3 Carl Roth GmbH, Karlsruhe 
NaH2PO4 Carl Roth GmbH, Karlsruhe 
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NaOH Carl Roth GmbH, Karlsruhe 
OptiPrepTM Density Gradient Medium Sigma-Aldrich, Steinheim 
Phenol Carl Roth GmbH, Karlsruhe 
Phenol Red Solution Sigma-Aldrich, Steinheim 
PMSF Roche Diagnostics, Mannheim 
Protease Inhibitor Cocktail Complete, EDTA-free Roche Diagnostics, Mannheim 
SDS Carl Roth GmbH, Karlsruhe 
Sucrose Merck Calbiochem, Darmstadt 
TEMED Sigma-Aldrich, Steinheim 
TMB Sigma-Aldrich, Steinheim 
Triton®  X-100  Serva Feinbiochemica, Heidelberg 
Trizma®  base (Tris)  Sigma-Aldrich, Steinheim 
Tween®  20  Gerbu, Gaibach 
2-mercaptoethanol  Carl Roth GmbH, Karlsruhe  
2-Propanol  Merck Calbiochem, Darmstadt  
6X DNA Loading Dye  Thermo Fisher Scientific, Darmstadt  
 
2.2 Reagents for Bacteria Cultivation 
Ampicillin Sigma-Aldrich, Steinheim 
BactoTM Agar Becton Dickinson, Heidelberg 
BactoTM Tryptone Carl Roth GmbH, Karlsruhe 
Bluogal Invitrogen, Karlsruhe 
Chloramphenicol Sigma-Aldrich, Steinheim 
Gentamycin Sigma-Aldrich, Steinheim 
IPTG AppliChem, Darmstadt 
Kanamycin Sigma-Aldrich, Steinheim 
LB Medium Carl Roth GmbH, Karlsruhe 
Tetracycline Sigma-Aldrich, Steinheim 
X-gal Sigma-Aldrich, Steinheim 
Yeast extract  Gerbu, Gaibach 
 
2.3 Reagents for cell culture 
Dulbecco’s Modified Eagle’s Medium (DMEM) Sigma-Aldrich, Steinheim 
Dulbecco’s Phosphate Buffered Saline (D-PBS) Invitrogen, Karlsruhe 
Dulbecco’s Phosphate Buffered Saline (D-PBS) 
(+CaCl2 +MgCl2) 
Thermo Fisher Scientific, Darmstadt 
Dimethylsulfoxid (DMSO) Carl Roth GmbH, Karlsruhe 
EX-CELLTM 405 serum-free insect cell medium Sigma-Aldrich, Steinheim 
Fetal Bovine Serum (FCS) Linaris GmbH, Wertheim 
Grace’s Insect Medium, supplemented Sigma-Aldrich, Steinheim 
Hygromycin B Sigma-Aldrich, Steinheim 
Opti-MEM serum-free medium Invitrogen, Karlsruhe 
Penicillin/Streptomycin (10,000 U/ml) Thermo Fisher Scientific, Darmstadt 
TNM-FH Insect Medium Sigma-Aldrich, Steinheim 
Trypan blue Biochrom, Berlin 
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Turbofect in vitro Transfection Reagent Thermo Fisher Scientific, Darmstadt 
0.25% Trypsin/EDTA Invitrogen, Karlsruhe 
Pluronic F-68 Sigma-Aldrich, Steinheim 
 
2.4 Kits 
AllPrep DNA/RNA Mini Kit  Qiagen (Hilden, Germany)  
AxygenTM AxyPrepTM Plasmid Miniprep Kit  Fisher Scientific GmbH, Schwerte  
CloneJET PCR Cloning Kit  Thermo Fisher Scientific, Darmstadt  
High Pure PCR Product Purification Kit  Roche Diagnostics, Mannheim  
TURBO DNA-freeTM Kit  Thermo Fisher Scientific, Darmstadt  
QIAamp DNA Mini Kit  Qiagen, Hilden  
QIAGEN®  Plasmid Midi Kit  Qiagen, Hilden  
QIAGEN®  Plasmid Maxi Kit  Qiagen, Hilden  
QIAquick®  Gel Extraction Kit  Qiagen, Hilden  
RNeasy®  Mini Kit  Qiagen, Hilden  
 
2.5 DNA and protein size markers 
GeneRulerTM 1 kB DNA Ladder  Thermo Fisher Scientific, Darmstadt 
PageRulerTM Plus Prestained Protein Ladder  Thermo Fisher Scientific, Darmstadt 
 
2.6 Universal enzymes 
Benzonase Merck Calbiochem, Darmstadt 
DreamTaqTM Green DNA Polymerase Thermo Fisher Scientific, Darmstadt  
Dream TaqTM Green PCR Master Mix (2X) Thermo Fisher Scientific, Darmstadt 
Phusion®  High-Fidelity DNA Polymerase  New England BioLabs, Frankfurt/Main 
RevertAid Reverse Transcriptase  Thermo Fisher Scientific, Darmstadt  
RNase A/T1 Mix  Thermo Fisher Scientific, Darmstadt  
T4 DNA Ligase  New England BioLabs, Frankfurt/Main  
 
2.7 Restriction enzymes 
 
 
 
 
 
 
 
 
 
 
 
 
 
AgeI New England BioLabs, Frankfurt/Main 
BamHI-HF New England BioLabs, Frankfurt/Main  
DpnI New England BioLabs, Frankfurt/Main 
DraIII New England BioLabs, Frankfurt/Main 
EcoRI-HF New England BioLabs, Frankfurt/Main 
HinDIII-HF New England BioLabs, Frankfurt/Main 
NheI-HF New England BioLabs, Frankfurt/Main 
SalI New England BioLabs, Frankfurt/Main 
SacII New England BioLabs, Frankfurt/Main 
SphI New England BioLabs, Frankfurt/Main 
XbaI New England BioLabs, Frankfurt/Main 
XmaI New England BioLabs, Frankfurt/Main 
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2.8 Consumables 
AmershamTM HybondTM P 0.45 PVDF  Th. Geyer, Renningen  
Capillary tips (200 μl)  Biozym, Hessisch Oldendorf  
Cell culture dishes (6, 10, 15 cm)  TPP, Trasadingen, Switzerland  
Cell culture flasks (25, 75 cm2)  TPP, Trasadingen, Switzerland  
Cell culture flasks 175 cm2  Greiner Bio-One GmbH, Frickenhausen  
Cell culture plates (6 well)  BD Falcon, Heidelberg  
Cell culture plates (12, 24, 96 well)  Greiner Bio-One GmbH, Frickenhausen  
Cell scraper  Corning Sigma, München  
Centrifuge Tubes (14 x 89 mm) Beckman Coulter.Inc, USA 
Cover slides Menzel-Gläser  Thermo Fisher Scientific, Darmstadt 
Facial tissues  WEPA Professional GmbH, Arnsberg  
Gloves (Microflex®  XCEED)  MICRFLEX, USA  
GSTrapTM FF GE Healthcare Bio-Science, Sweden 
Incidin®  Foam  Ecolab Deutschland, Monheim am Rhein  
Luer-Lock Syringe (50 ml)  Terumo Detuschland, Eschborn  
Millex-HV filter unitt, PVDF  Merck Millipore, Darmstadt  
Minisart Syringe Filter  Sartorius, Göttingen  
MultiplateTM PCR Plates 96-well, clear  Bio-Rad, München  
Needles, sterile (18G, 20G, 25G, 27G)  Braun, Melsungen  
Nunc®  Cryo Tubes  Sigma-Aldrich, Steinheim  
NuncTM F96 MicroWellTM White Polystyrene 
Plate  
Thermo Fisher Scientific, Darmstadt  
Objektträger Superfrost®  Plus  Carl Roth GmbH, Karlsruhe  
Optical Adhesive Covers MicroAmp  ABiosystems, Foster City, USA  
PCR SingleCap 8er Soft Strips  Biozym, Hessisch Oldendorf  
Phase Lock Gel Light  5PRIME GmbH, Hilden  
Pipette Tips (10, 200, 1000 μl)  Steinbrenner, Gieß en  
Pipette Tips RAININ (200 μl)  Steinbrenner, Gieß en  
Polysorb Nunc-Immuno plates  Thermo Fisher Scientific, Darmstadt  
Protein LoBind Tube 1.5ml Eppendorf, Hamburg 
Precision Wipes Kimberly-Clark Professional, Reigate, UK 
Scalpels, disposable Feather Safety Razor, Osaka, Japan 
Special autoclavable bags Nerbe plus GmbH, Winsen/Luhe 
Syringes, single use 1 ml Th. Geyer GmbH, Renningen 
Reaction Tubes (0.5, 1.5 and 2.0 ml) Eppendorf, Hamurg 
X-ray films Super RX  X-ray films Super RX  
 
2.9 Laboratory equipment 
Analytical scale ABJ-120-4NM  Kern & Sohn GmbH, Balingen  
Autoradiography Cassettes  Kodak, Stuttgart  
Bacterial shaker G25  Infors, Bottmingen, CH  
Centrifuge Heraeus Pico 17  Thermo Fisher Scientific, Darmstadt  
Centrifuge Heraeus Fresco 17  Thermo Fisher Scientific, Darmstadt  
Centrifuge Megafuge 1.0R  Heraeus, Hanau  
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Centrifuge Sprout  Biozym, Hessisch Oldendorf  
Centrifuge Rotina 380R  M&S Laborgeräte, Wiesloch  
Confocal Olympus FluoView FV1000 Olympus, Hamburg 
Developing machine CURIX 60  AGFA, Cologne  
Easy-CastTM Electrophoresis System  Thermo Fisher Scientific, Darmstadt  
EVOS®  XL Core Imaging System  Thermo Fisher Scientific, Darmstadt  
Freezer profi line  Liebherr, Ludwigshafen  
Freezer VIPTM Series -86°C  Sanyo, USA  
Fridge Premium  Liebherr, Ludwigshafen  
Gel documentation system GELSTICK  INTAS Science Imaging Instruments  
Impulse Sealer  Tew Electric Heating Equipment, Taiwan  
Incubator C200  LaBoTect, Göttingen  
Kern EMB 1200-1 Tischwaage 1200 g  KERN & SOHN GmbH, Balingen  
Liquid nitrogen tank CHRONOS Biosafe  Messer, Griesheim  
Magnetic stirrer MR3000  Heidolph Instruments, Schwabach  
Microscope Dialux 22  Ernst Leitz Wetzlar GmBH, Wetzlar  
Microscope Olympus CK2  Olympus, Hamburg  
Microwave  DéLonghi GmbH, Seligenstadt  
Mini-PROTEAN®  3 Cell  Bio-Rad, München  
Mini PROTEAN®  Trans Blot  Bio-Rad, München  
Moser ChroMini Pro Trimmer  Wahl GmbH, Unterkirnach  
Moser Trimmer 1556  Wahl GmbH, Unterkirnach  
Multichannel Pipette RAININ (50-200 μl)  Eppendorf, Hamburg  
MyCycler thermal cycler  Bio-Rad, München  
Neubauer hemocytometer  Bender&Hobein, Bruchsal  
Overhead shaker REAX2  Heidolph Instruments, Schwabach  
Peltier Thermal Cycler PTC-200  MJ Research, St. Bruno, Canada  
pH-meter 761 Calimatic  Knick, Berlin  
Pipette Boy Acu  Integra Biosciences GmbH, Fernwald  
Pipettes Research (2, 10, 20, 100, 200, 1000 μl)  Eppendorf, Hamburg  
Plate Reader SPECTROstar Nano  BMG LABTECH Ortenberg  
Power supply PowerPacTM HC/basic  Bio-Rad, München  
Roller Mixer SRT9D  Stuart, USA  
Spectrophotometer NanoDrop®  ND-1000  NanoDrop, USA  
STERI-CULT 200 Incubator  Forma Scientifc, Marietta, USA  
SterilGARD Hood  Baker Company, Sanford, USA  
Thermal Cycler C1000TM  Bio-Rad, München  
Thermomixer compact/pico  Eppendorf, Hamburg  
UV table N90  Benda Konrad, Wiesloch  
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2.10 Buffers and Solutions 
Ammonium persulfate (APS)  10% (w/v) in water  
Ampicillin  100 mg/ml 
Buffer L 40 mM Tris 
200 mM NaCl 
1 mM EDTA pH 8.2 
2 mM DTT 
Blocking buffer (Immunofluorescence) 1% BSA 
0.02% Tween 20 
in PBS, filtered 
Casein blocking buffer 0.2 % (w/v) casein in PBS-T 
Cesium chloride solution 57.5 % CsCl (w/v) in 
VLP extraction buffer 
Chloramphenicol stock solution 34 mg/ml 
Coating buffer (ELISA) 50 mM carbonate buffer pH 9.6: 
1 part 50 mM Na2CO3 
4 parts 50 mM NaHCO3 
DMEM Cryo Medium  10% DMSO  
20% FCS  
70% DMEM  
DPBS/0.8M NaCl (50 ml) 42 ml DPBS (+MgCl2 + CaCl2) 
8 ml 5M NaCl 
2 x HBS  15 ml 0.5M HEPES 
14 ml 5M NaCl 
0.75 ml 0.5M Na2HPO4  
add to 250 ml ddH2O 
adjust the pH exactly to 7.13 
27% Iodiaxanol (4 ml) 1.8 ml OptiprepTM Density Gradient 
Medium 
2.2 ml DPBS/0.8M NaCl 
33% Iodiaxanol (4 ml) 2.2 ml OptiprepTM Density Gradient 
Medium 
1.8 ml DPBS/0.8M NaCl 
39% Iodiaxanol (4 ml) 2.6 ml OptiprepTM Density Gradient 
Medium 
1.3 ml DPBS/0.8M NaCl 
80 µl Phenol red solution 
Kanamycin  50 mg/ml  
PBS (10 x)  1.24 M NaCl  
0.22 M Na2HPO4  
0.1 M KH2PO4  
adjust the pH exactly to 7.2 
PBST (1 x)  1X PBS, pH 7.2  
0.1% (v/v) Tween 20  
Permeabilisation buffer  1% BSA 
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(Immunofluorescence) 0.02% Tween 20 
0.2% Triton X-100 
in PBS, filtered 
Pseudovirus lysis buffer 1 ml DPBS (+MgCl2 + CaCl2) 
58.3 µl 10% Briji58 
6.7 µl RNAse A/T cocktail 
RIPA Buffer  20 mM Tris pH 7.5  
150 mM NaCl  
1 mM Na2EDTA  
1 mM EGTA  
1% NP-40  
1% sodium deoxycholate  
SDS Loading Dye (5 x)  1% (w/v) SDS  
0.03% (w/v) bromophenol blue  
12.5% (v/v) 2-mercaptoethanol  
5 mM EDTA, pH 8.0  
47.3% (v/v) glycerol  
0.3 M Tris, pH 6.8  
2.5 mM NaF  
SDS PAGE Running Buffer (10 x)  10% SDS  
0.25 M Tris  
1.9 M Glycine  
Substrate buffer (ELISA) 100 mM sodium acetate 
adjust to pH 6 with acetic acid 
Sucrose solution 30 % sucrose (w/v) in 
VLP extraction buffer 
TAE Buffer (50 x)  2 M Tris  
0.25 M NaAc  
0.05 M EDTA, pH 8.0  
adjust to pH 7.8 with acetic acid  
TBS (10 x)  Tris 0.5 M  
NaCl 1.5 M  
adjust to pH 7.5  
TBST (1 x)  1X TBS, pH 7.5  
0.1% (v/v) Tween 20  
TMB stock solution 10 mg/ml TMB in DMSO 
Transfection buffer (for Sf9 cells) 25 mM Hepes 
125 mM CaCl2  
140 mM NaCl 
adjust to pH 7.0, 7.1, 7.2 
VLP extraction buffer 5 mM MgCl2 
5 mM CaCl2 
150 mM NaCl 
0.01 % Triton X 100 
20 mM HEPES pH 7.4 
2.5 mM PMSF (freshly added) 
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2.11 Bacteria 
DH10MultiBacCre Electrocompetent E. coli Kindly provided by Prof. Dr. M. Müller, DKFZ  
E. coli BL21  Kindly provided by Prof. Dr. M. Müller, DKFZ 
E. coli Rosetta Kindly provided by Prof. Dr. M. Müller, DKFZ 
TOP10 Chemically Competent E. coli Invitrogen, Karlsruhe 
 
2.12 Cell lines 
Cell line Properties Medium 
HEK 
293TT 
Human embryonic kidney cells, 
transformed with E1A/B of adenovirus 
5, stably expressing two gene copies of 
SV40 large T-antigen 
DMEM supplemented with 10% Fetal 
calf serum, 1%Penicillin/Streptomycin 
and 1% L-glutamine, 125 µg/ml 
Hygromycin B 
HeLaT HPV18 human cervical carcinoma cell 
line stably expressing one copy of 
SV40 T-antigen under control of a 
CMV promotor 
DMEM supplemented with 10% Fetal 
calf serum, 1%Penicillin/Streptomycin 
and 1% L-glutamine, 125 µg/ml 
Hygromycin B 
HeLa HPV18 human cervical carcinoma cell 
line 
DMEM supplemented with 10% Fetal 
calf serum, 1%Penicillin/Streptomycin 
and 1% L-glutamine 
SF9 Insect cell line, clonal isolated from 
Spodoptera frugiperda Sf21 cells 
TNM-FH insect medium supplemented 
with 10% Fetal calf serum, 1% 
Penicillin/Streptomycin and 1% L-
glutamine 
TN-High-
Five 
Insect cell line, ovarian cells of the 
cabbage looper Trichoplusia ni 
EX-CELLTM 405 serum-free medium 
supplemented with 1% 
Penicillin/Streptomycin and 1% L-
glutamine 
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2.13 Oligonucleotides  
All primers were synthesized by Sigma-Aldrich, Germany. 
Primers for construction of pseudovirus pGEM-IRES expression plasmids               linker    Tan [°C] 
MnPV L1LONG: start codon at 5701 bp - Codon optimized 
For: L1L-NheI-Forward 5’- CTA GCT AGC GCC ACC ATG AGC TAT 
ATT G - 3’ 
NheI 
60°C 
Rev: L1L-SalI-Reverse 5’- ACG CGT CGA CTC ACT TCT TGC GTC 
TCT T - 3’   
SalI 
MnPV L1MIDDLE: start codon at 5722 bp - Codon optimized 
For: L1middle-NheI-
Forward 
5’- CTA GCT AGC GCC ACC ATG GGT AGG 
ACC ATC - 3’ 
NheI 
60°C 
Rev: L1L-SalI-Reverse 5’- ACG CGT CGA CTC ACT TCT TGC GTC 
TCT T - 3’   
SalI 
MnPV L2: start codon at 4248 bp - Codon optimized  
For: L2-NheI-Forward 5’- CTA GCT AGC ATG AGC CGC CGC CGC 
AAG C - 3’ 
NheI 
62°C 
Rev: MnL2 hum-BamHI-
R* 
5’- GGA TCC TCA TGC GGC GAG CAC CCC G - 
3’   
BamHI 
*kindly provided by Dr. Kai Schäfer, DKFZ Heidelberg 
 
Primers for site-directed mutagenesis of pseudovirus expression plasmids               linker    Tan [°C] 
Mutation on 2nd ATG of L1LONG:  From Methionine (ATG) to Alanine (GCG) - Codon optimized 
For: L1L-1.5thM-NheI-
Forward-1 
5’-GCT AGC GCC ACC ATG AGC TAT ATT 
GGC GCC ATT GCG GGT AGG ACC ATC AT- 3’ 
NheI 
62°C 
Rev: L1L-SalI-Reverse 5’- ACG CGT CGA CTC ACT TCT TGC GTC TCT 
T - 3’   
SalI 
Mutation on 3rd ATG of L1LONG:  From Methionine (ATG) to Alanine (GCG) - Codon optimized 
For: L1-L-Forward1 5’-GCT GGG ATA TCC ATC TTC CAG GCG GCC TAT TG 
- 3’ 
60°C 
Rev: L1-L-Reverse1 5’- CA ATA GGC CGC CTG GAA GAT GGA TAT CCC 
AGC - 3’ 
 
Primers for construction of pPK-CMV E3-MnPVL1 and L2 expression plasmids     linker    Tan [°C] 
MnPV L1LONG: start codon at 5701 bp - Codon optimized with HA tag 
For: pCMV-L1L- EcoRI 5’- CCG GAA TTC GCC ACC ATG AGC TAT 
ATT GGC GCC ATT GCG -3’ 
EcoRI 
60°C 
Rev: pCMV-L1L-BamHI-1 5’- CGC GGA TCC CTT CTT GCG TCT CTT TG - 
3’   
BamHI 
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MnPV L1MIDDLE: start codon at 5722 bp - Codon optimized with HA tag 
For: pCMV-L1mid- EcoRI 5’- CCG GAA TTC GCC ACC ATG GGT AGG 
ACC ATC -3’ 
EcoRI 
60°C 
Rev: pCMV-L1L-BamHI-1 5’- CGC GGA TCC CTT CTT GCG TCT CTT TG - 
3’ 
BamHI 
MnPV L1SHORT: start codon at 5794 bp - Codon optimized with HA tag 
For: pCMV-L1S- EcoRI 5’- CCG GAA TTC GCC ACC ATG GCC TAT 
TGG CTC C -3’ 
EcoRI 
60°C 
Rev: pCMV-L1L-BamHI-1 5’- CGC GGA TCC CTT CTT GCG TCT CTT TG - 
3’   
BamHI 
MnPV L1LONG: start codon at 5701 bp - Codon optimized without HA tag 
For: pCMV-L1L- EcoRI 5’- CCG GAA TTC GCC ACC ATG AGC TAT 
ATT GGC GCC ATT GCG -3’ 
EcoRI 
60°C 
Rev: pCMV-L1L-BamHI 5’- CGC GGA TCC TCA CTT CTT GCG TCT CTT 
- 3’   
BamHI 
MnPV L1MIDDLE: start codon at 5722 bp - Codon optimized without HA tag 
For: pCMV-L1mid- EcoRI 5’- CCG GAA TTC GCC ACC ATG GGT AGG 
ACC ATC -3’ 
EcoRI 
60°C 
Rev: pCMV-L1L-BamHI 5’- CGC GGA TCC TCA CTT CTT GCG TCT CTT 
- 3’   
BamHI 
MnPV L1SHORT: start codon at 5794 bp - Codon optimized without HA tag 
For: : pCMV-L1S- EcoRI 5’- CCG GAA TTC GCC ACC ATG GCC TAT 
TGG CTC C-3’ 
EcoRI 
60°C 
Rev: pCMV-L1L-BamHI 5’- CGC GGA TCC TCA CTT CTT GCG TCT CTT 
- 3’   
BamHI 
MnPV L2: start codon at 4248 bp - Codon optimized without HA tag  
For: : L2-EcoRI-Forward 5’- CCG GAA TTC GCC ACC ATG AGC CGC 
CGC CGC AAG C - 3’ 
EcoRI 
60°C 
Rev: L2-BamHI-Reverse 5’- CGC GGA TCC TCA TGC GGC GAG CAC 
CCC G - 3’   
BamHI 
 
 
 
Primers for construction of pGEM-MnPV L1LONG 3rd mutation plasmids                  linker    Tan [°C] 
MnPV L1LONG: start codon at 5701 bp 
For: MnPVL1long-
Forward 
5’- ATG TCA TAT ATA GGG GCT ATA -3’ T/A 
58°C 
Rev: MnPVL1long-
Reverse 
5’- CTA TTT TTT TCT CCG CTT GGT GGA -3’ T/A 
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Mutation on 3rd ATG of L1LONG:  From Methionine (ATG) to Alanine (GCG) 
For: OF 5’- CTC TTC GCT ATT ACG CCA GC -3’ 
SacII 58°C Rev: IR 5’- CCA GTA CGC CGC CTG AAA AAT AGA 
TAT GCC TGC GC -3’ 
For: IF 5’- CT ATT TTT CAG GCG GCG TAC TGG CTG 
CCT AAT AAC -3’ AgeI 58°C 
Rev: OR 5’- ATA CAC CAT GCA AGC CGT TGC -3’ 
 
Primers for construction of pFBDM-MnPV L1 expression plasmids                         linker    Tan [°C] 
MCSI: MnPV L1LONG: start codon at 5701 bp  
For: MnPVL1-2ndM-
EcoRI 
5’- CCG GAA TTC ATG TCA TAT ATA GGG 
GCT ATA GCG GGA CGG ACT ATT - 3’  
EcoRI 
60°C 
Rev: MnPVL1-HinDIII 5’- CCC AAG CTT CTA TTT TTT TCT CCG CTT 
GGT GGA - 3’ 
HinDI
II 
MCSII: MnPV L1LONG: start codon at 5701 bp  
For: MnPVL1-2ndM-SmaI 5’- TCC CCC GGG ATG TCA TAT ATA GGG 
GCT ATA GCG GGA CGG ACT ATT - 3’  
XmaI 
60°C 
Rev: MnPVL1-SphI 5’- A GCA TGC CTA TTT TTT TCT CCG CTT 
GGT GGA - 3’ 
SphI 
MCSI: MnPV L1MIDDLE: start codon at 5722 bp  
For: MnPVL1mid-EcoRI 5’- CCG GAA TTC ATG GGA CGG ACT ATT 
ATC TAC ACC - 3’ 
EcoRI 
60°C 
Rev: MnPVL1-HinDIII 5’- CCC AAG CTT CTA TTT TTT TCT CCG CTT 
GGT GGA - 3’  
HinDI
II 
MCSII: MnPV L1MIDDLE: start codon at 5722 bp  
For: MnPVL1mid-SmaI 5’- TCC CCC GGG ATG GGA CGG ACT ATT 
ATC TAC ACC - 3’ 
XmaI 
60°C 
Rev: MnPVL1-SphI 5’- A GCA TGC CTA TTT TTT TCT CCG CTT 
GGT GGA - 3’ 
SphI 
MCSI: MnPV L1SHORT: start codon at 5794 bp  
For: MnPVL1S-EcoRI 5’- CCG GAA TTC ATG GCG TAC TGG CTG 
CCT AAT AAC - 3’ 
EcoRI 
60°C 
Rev: MnPVL1-HinDIII 5’- CCC AAG CTT CTA TTT TTT TCT CCG CTT 
GGT GGA - 3’ 
HinDI
II 
MCSII: MnPV L1SHORT: start codon at 5794 bp  
For: MnPVL1S-XmaI 5’- TCC CCC GGG ATG GCG TAC TGG CTG 
CCT AAT AAC - 3’ 
XmaI 
60°C 
Rev: MnPVL1-SphI 5’- A GCA TGC CTA TTT TTT TCT CCG CTT 
GGT GGA - 3’ 
SphI 
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Detection of Inserts in MultiBac multiple cloning sites*                                                        TM [°C] 
MCSI For: TS#32 (MCS1-100bp) 5’ - AAT GAT AAC CAT CTC GC - 3’ 55 
Rev: TS#33 (MCS1 +100bp) 5’ - TAT GTT TCA GGT TCA GG - 3’ 55 
MCSII For: TS#30 (MCS2 -50bp) 5’ - GTC ATA GCG CGG GTT CC - 3’ 61 
Rev: TS#31 (MCS2 +100bp) 5’ - CGG ACC TTT AAT TCA ACC - 3’ 61 
*kindly provided by Dr. Kai Schäfer, DKFZ Heidelberg 
 
 
Primers for construction of pGEX-MnPV L1 expression plasmids                             linker    Tan [°C] 
MnPV L1MIDDLE: start codon at 5722 bp  
For: MnPV-L1middle-
XmaI 
5’ -TCC CCC CGG GCC ATG GGA CGG ACT 
ATT ATC TAC ACC - 3’ 
XmaI 
60°C 
Rev: MnPV-L1-SaII-1 5’ - ACG CGT CGA CTT TTT TTC TCC GCT 
TGG TGG - 3’ 
SalI 
MnPV L1NT-41aa: start - stop:  5701bp to 5823bp  
For: MnPV-L1NT-XmaI 5’ -TCC CCC CGG GCC ATG TCA TAT ATA 
GGG GCT ATA - 3’ 
XmaI 
60°C 
Rev: MnPV-L1NT-SaII-41 5’ -ACG CGT CGA CCT TCT GGT TAT TAG 
GCA GCC - 3’ 
SalI 
 
 
Primers for construction of pJET-MnPV URR genome plasmid (Gibson Assembly)    Size    Tan [°C] 
Fragment1: Use pJET-MnPV URR 1.8 as the template 
For: FYY-15 5’ - TTT TCA GCA AGA TTA TAG TCG ACA 
GCA CGC TG - 3’ 
2957bp 60°C 
Rev: FYY-16 5’ - GTC TCC TCC CCA TCC TCA TAC ATG 
CAC ATC AGT TCC TC - 3’ 
Fragment2: Use pUC19-MnPV L2 as the template 
For: FYY-17 5’ - TGT GCA TGT ATG AGG ATG GGG AGG 
AGA CAC TG - 3’ 
1681bp 60°C 
Rev: FYY-18 5’ - TTC TCC TTC TAG ACA TGC TAA TAT 
TAG TAG GTT AGT ACT GTG TAA AGG - 3’ 
Fragment3: Use pUC19-MnPV L2 as the template 
For: FYY-19 5’ - TAA TAT TAG CAT GTC TAG AAG GAG 
AAA GCG ACA TAC - 3’ 
2468bp 60°C 
Rev: FYY-20 5’ - AGC ATC AGA TGA CAC TAG TGA CCC 
TGA CGG AG - 3’ 
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Fragment4: Use pJET-MnPV URR 1.8 as the template 
For: FYY-21 5’ - CAG GGT CAC TAG TGT CAT CTG ATG 
CTG TAC TG - 3’ 
3685bp 60°C 
Rev: FYY-22 5’ - GCT GTC GAC TAT AAT CTT GCT GAA 
AAA CTC GAG - 3’ 
 
Primers for construction of pUC19-MnPV URR mutation genome plasmids           linker    Tan [°C] 
Mutation on 1st and 2nd ATG of L1:  From Methionine (ATG) to Alanine (GCG) 
For: PUC-L1-1F 5’ - AGA GTA TAG AAC TCA GCA CC - 3’ 
DraIII 60°C Rev: PUC-L1Lmid-1R 5’ - GC TAT AGC CCC TAT ATA TGA CGC GGG 
GAC GAG CAC TGT CCC TA - 3’ 
For: PUC-L1Lmid-2F 5’ - TCA TAT ATA GGG GCT ATA GCG GGA 
CGG ACT ATT ATC TAC AC - 3’ DraIII 60°C 
Rev: PUC-L1-2R 5’ - CCA TGT CAC CAT CCT CAA TC - 3’ 
Mutation on 3rd ATG of L1:  From Methionine (ATG) to Alanine (GCG) 
For: PUC-L1-1F 5’ - AGA GTA TAG AAC TCA GCA CC - 3’ 
DraIII 60°C Rev: PUC-L1S-1R 5’ - CCA GTA CGC CGC CTG AAA AAT AGA 
TAT GCC TG - 3’ 
For: PUC-L1S-2F 5’ - CT ATT TTT CAG GCG GCG TAC TGG CTG 
CCT AAT AAC - 3’ DraIII 60°C 
Rev: PUC-L1-2R 5’ - CCA GTC ACC ATC CTC AAT C - 3’ 
 
Primers for construction of pUC19-MnPV URR L1NT genome plasmids                   Size      Tan [°C] 
Fragment1: Use pUC19-MnPV URR L1Lmid M as the template 
For: F1-F 5’ - CTA CTG CTT GAC GGG CTA AGA GTG 
ATC TGT CCG CG - 3’ 
2343bp 62°C 
Rev: F1-R 5’ - GTT AAT GAG TAC CTC TTT GCT TCC 
TCT TTG AAC CGC - 3’ 
Fragment2: Use pUC19-MnPV URR L1Lmid M as the template 
For: F2-F 5’ - AGG AAG CAA AGA GGT ACT CAT TAA 
CAG GAA CTT GG - 3’ 
2660bp 62°C 
Rev: F2-R 5’ - GCA GCC AGT ACG CCA TGG GGA CGA 
GCA CTG TCC C - 3’ 
Fragment3: Use pUC19-MnPV URR L1Lmid M as the template 
For: F3-F 5’ - CTC GTC CCC ATG GCG TAC TGG CTG 
CCT AAT AAC C - 3’ 
2633bp 62°C 
Rev: F3-R 5’ - GTA GAA AAG ATC AAA GGA TCT TCT 
TGA GAT C - 3’ 
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Fragment4: Use pUC19-MnPV URR L1Lmid M as the template 
For: F4-F 5’ - CAA GAA GAT CCT TTG ATC TTT TCT 
ACG GGG TCT G - 3’ 
2756bp 62°C 
Rev: F4-R 5’ - GAT CAC TCT TAG CCC GTC AAG CAG 
TAG ATG TTC - 3’ 
Start codons are in black. Stop codons are in red.  Mutated start codons are in green. Tan= Annealing 
temperature; TM = Melting temperature. 
 
2.14 Antibodies 
Antibody Source Application 
Alexa Fluor 488 donkey anti-
rat IgG (H+L) 
Invitrogen; Cat.#: A21208 IF: 1: 500 
Alexa Fluor 594 goat anti-
mouse IgG2a (γ2a) 
Invitrogen; Cat.#: A21135 IF: 1: 2,000 
Anti-actin (human) mouse 
monoclonal 
MP Biomedical; Cat.#: 69100 WB: 1: 10,000 
Anti-HA (3F10) rat 
monoclonal 
Roche; Cat.#: 11867423001 WB:1: 1,000; IF: 1: 1000 
Goat anti-Mouse IgG (H+L) 
HRP  
Promega; Cat.#: W402B ELISA: 1: 10,000;  
WB: 1: 10,000 
Goat anti-Rat IgG (H+L) HRP  JacksonImmunoResearch, 
Cat.#: 112-035-143 
WB: 1: 10,000 
Mouse monoclonal anti-
MnPV VLP (2E2; 2D6; 2D11; 
5E5; 3H8) 
Selfmade from Laura 
Katharina Schmitt, DKFZ 
ELISA: 1: 20; IF: 1: 300 
Mouse monoclonal anti-
SV40tag KT3 
Selfmade from Dr. Tim 
Waterboer, DKFZ 
ELISA: 1: 300; WB: 1: 1000 
Serum mix Sera of five MnPV infected 
tumor bearing animals 
ELISA: 1: 1000; WB: 1: 500 
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3. Methods 
3.1 Animals experiments 
3.1.1 Animals following-up experiments 
Mastomys coucha from MnPV naturally infected breeding colony were maintained at 22-
24°C with 55% relative humidity, mouse breeding diet and water ad libitum. For the follow-up 
experiment, animals were monitored for the duration of their life until they had to be sacrificed 
due to tumor development, eye inflammation or decrepitude. The blood was taken from the 
submandibular vein at intervals of 2 weeks at the early age and 8 weeks at the late age. Mastomys 
coucha at DKFZ are housed and handled in accordance with German and European statutes. All 
the animal experiments were undertaken with the approval of the responsible Animal Ethics 
Committee for the use and care of live animals (Regional Council of Karlsruhe, Germany). The 
Cyclosporine A (CsA) treatment and UV irradiation experiment was done in collaboration with Dr. 
Julita Mikulec and Dr. Daniel Hasche. Animals were fed with the immunosuppressant CsA with a 
concentration (125 mg/kg) starting from the age at 15 weeks. UV irradiation was performed with a 
dose of 450 mJ/ cm2 three times per week also starting from the age at 15 weeks. 
 
3.1.2 Serum 
Blood was taken from submandibular vein with a 25G needle when the animals were 
under Isoflurane anesthetized status. The blood droplets were collected in 1.5 ml EppiTM tubes and 
incubated at room temperature for 1 hour until it was completely clotted. The serum was carefully 
collected after centrifugation at 8000 rpm.  
 
3.2 Cloning and analysis of plasmids 
3.2.1 Cloning polymerase chain reaction (PCR) 
The polymerase chain reaction was performed to amplify the DNA sequences of respective 
inserts for plasmid construction. Specific primers were designed for amplification process, 
containing respective enzyme restriction sites at the 5’ end and a Kozak sequence in the upstream 
of start codon in some cases. All PCRs were performed by Phusion High-Fidelity DNA polymerase 
(NEB) according to the manufacturer’s instructions: 
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Component 50 µl Reaction 
Nuclease - free water to 50 µl 
5 x Phusion HF buffer 10 µl 
10 mM dNTPs 1 µl 
10 µM Forward Primer 2.5 µl 
10 µM Reverse Primer 2.5 µl 
Template DNA variable 
DMSO (optional) (1.5 µl ) 
Phusion DNA Polymerase 0.5 µl 
 
Thermocycling conditions for a routine PCR: 
 
Step Temperature Time 
Initial Denaturation 98 °C 30 s 
Denaturation 
Annealing  
Elongation 
98 °C 
56-62°C 
72 °C 
5-10 s 
10-30 s 
15-30 s/kb 
Final Extension 72 °C 5-10 min 
 
3.2.2 Restriction enzyme digestion and ligation 
Prior to the restriction enzyme digestion, PCR product of insert was purified by QIAquick 
Gel Extraction Kit according to the manufacturer’s protocols. The cutting of purified PCR 
products and vector backbone were performed using restriction enzyme for 1-4 hours according to 
NEB protocol: 
Component Reaction 
Restriction Enzyme 1 10 units - 20 units 
Restriction Enzyme 2 10 units - 20 units 
DNA 1 - 10 µg 
10 x NEBuffer 5 µl 
Total Reaction Volume 50 - 100 µl 
 
DNA fragments were separated by agarose gel electrophoresis (1-1.2% agarose in 1 x TAE 
buffer) and visualized by UV light after ethidium bromide staining. DNA fragments were linked in 
a molecular ration of 1: 5 (vector to insert) by T4 DNA ligase (Thermo Fisher Scientific) overnight 
at 22°C. 
Component Reaction 
Linear vector DNA 20 - 100 ng 
Insert DNA 5: 1 molar ration over vector 
10 x T4 DNA Ligase Buffer 2 µl 
T4 DNA Ligase 1 Weiss U 
Nuclease - free water to 20 µl 
25-35 cycles 
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3.2.3 Transformation of competent bacteria  
1-5 µl containing 1pg-100 ng of plasmid DNA was added to NEB DH5α or TOP10 
competent cells. The mixture was incubated for 30 min on ice and followed by a heat shock at 
42°C for 30s. The bacteria were then put on ice for 5 min and shaken in 250 µl SOC medium at 
37°C for one hour. 50-100 µl of transformed cells were plated on agar plates with respective 
antibiotics and incubated overnight at 37°C. 
 
3.2.4 Plasmids preparation and sequencing 
A single colony was picked from selective agar plate and incubated in 3 - 4 ml LB medium 
for 8 hours at 37°C. Plasmid DNA was isolated by using AxygenTM Plasmid Miniprep Kit according 
to standard protocol and sent for sequencing. Large amounts of plasmid DNA were prepared by 
QIAGEN Plasmid Midi Kit and glycerol stocks were made for long term storage at -80°C.  
 
3.2.5 Construction of pseudovirus pGEM-IRES expression plasmids 
For production of MnPV pseudoviruses, plasmids exclusively encoding L1 variants and L2 
gene were used. The MnPV L1LONG, L1MIDDLE L1SHORT and L2 coding sequences derived from codon-
optimized MnPV sequences were synthesized by GenScript Company from Dr. Kai Schäfer (DKFZ, 
Heidelberg). The inserts were amplified by PCR and subcloned into pGEM-IRES expression 
backbone, which was kindly provided by Prof. Dr. Martin Müller. The second and third ATG of 
L1LONG expression plasmid was mutated to GCG in order to guarantee unique L1LONG expression. 
The second ATG mutation was introduced by using PCR with a forward primer containing the 
GCG, whereas the third ATG was mutated by Phusion site-directed mutagenesis method. 
Similarly, the second methionine of L1MIDDLE expression plasmid was mutated to alanine for 
exclusive expression of L1MIDDLE.  
 
3.2.6 Construction of pPK-CMV-E3 expression plasmids 
The humanized MnPV L1LONG (2nd and 3rd ATG mutation to GCG), L1MIDDLE (3rd ATG 
mutation to GCG), L1SHORT and L2 coding sequence with or without stop codon, were PCR-
amplified from pGEM-IRES expression plasmids and subcloned into pPK-CMV-E3 vector with 
EcoRI and BamHI sites.  
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3.2.7 Construction of pGEX-4T-3 plasmids 
Native MnPV L1MIDDLE gene and N-terminal 1 - 41 amino acids of L1LONG ORF were PCR-
amplified from GST-MnPV-L1LONG plasmid [107]. The inserts were subcloned into pGEX-4T-3 
vector backbone, which contains an N-terminal GST-tag and a C-terminal SV40 tag, with XmaI 
and SalI sites. 
 
3.2.8 Construction of pFBDM plasmids and Multibac plasmids 
To ensure only L1LONG and L1MIDDLE gene expressed in the Multibac expression system, the 
2nd ATG of L1LONG was mutated by PCR-amplification with a forward primer containing the 
mutated nucleotides GCG. The 3rd ATG of L1LONG was mutated to GCG by overlapping-PCR 
method in pGEM-MnPV L1LONG plasmid. Two copies of MnPV native L1LONG (2nd and 3rd ATG 
mutation to GCG), L1MIDDLE (3rd ATG mutation to GCG) and L1SHORT genes were inserted into 
pFBDM vector with two multiple cloning sites MCSI (EcoRI/HinDIII) and MCSII (XmaI/SphI). 
These two copies genes are flanked by polyhedrin or p10 promoters, respectively, which present 
two expression cassettes in a head to head arrangement. Since pFBDM plasmids contain the 
sequences used for Tn7 transposition (Tn7L and Tn7R), the recombinant MultiBac bacmids were 
generated by transforming pFBDM plasmids into electrocompetent DH10MultiBacCre E. coli. 
Following electroporation (1.8 kV pulse), competent cells are shaken at 37°C for 8 hours and 
plated on agar containing kanamycin (50 μg/ml), gentamycin (7 μg/ml), ampicillin (100 μg/ml), 
tetracycline (10 μg/ml), BluoGal (100 μg/ml) and IPTG (40 μg/ml). White colonies were picked 
after 18-24h incubation at 37°C. Recombinant MultiBac bacmids were then isolated by QIAGEN®  
Plasmid Mini Kit followed by ethanol precipitation.  
 
3.2.9 Construction of pUC19-MnPV genome plasmids - Gibson assembly 
MnPV genome was amplified by a pair of primers containing a SalI restriction site into the 
MnPV upstream regulatory region. This sequence was inserted in to pJET1.2/blunt vector by Dr. 
Daniel Hasche (named pJET-MnPV URR 1.8 plasmid). However, this plasmid contains three 
mutations and the LB culture needs to be incubated at 22°C for two days for plasmid isolation. 
Therefore, the wildtype MnPV genome without any mutations was inserted into pJET1.2/blunt 
vector by Gibson assembly method. Briefly, Gibson assembly master mix allows for successful 
assembly of multiple DNA fragments. This is due to three different enzymatic activities: 
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exonuclease creates single-stranded 3’ overhangs; DNA polymerase fills in gaps within each 
annealed fragment and DNA ligase seals nicks. For construction of pJET-MnPV URR genome 
plasmid, two fragments were PCR-amplified from pJET-MnPV URR 1.8 vector and two fragments 
were PCR-amplified from pUC19-MnPV L2 to remove the mutations (from Dr. Kai Schäfer, DKFZ 
Heidelberg). The four fragments with a ratio of 2: 2: 2: 1 (fragment 1-4) were mixed with Gibson 
Assembly Master mix which was kindly provided by Dr. Guochao Wei as follows: 
Component Reaction  
Total Amount of Fragments 0.2 - 1 pmols 
Gibson Assembly Master mix 10 µl 
Deionized H2O 10 - x µl 
Total volume 20 µl 
 
The DNA mixture was incubated at 50°C for one hour and transformed in NEB DH5α 
competent cells. The successful pJET-MnPV URR genome plasmid was verified by sequencing the 
whole plasmid. 
 
Figure 3.2.9: The overview of Gibson Assembly method (adapted from Gibson Assembly Master Mix protocol 
from NEB) 
 
To construct pUC19-MnPV wt plasmid, the wildtype MnPV genome starting from the 
URR was cut by SalI enzyme from pJET-MnPV URR genome plasmid and inserted to pUC19 
vector. The pUC19 MnPV L1LMid mutation plasmid was constructed by introducing mutations 
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on 1st and 2nd ATG to GCG by overlapping PCR method using the primers in Chapter 2.13. The 
pUC19 MnPV L1S mutation plasmid was constructed by introducing the mutation on 3rd ATG to 
GCG by overlapping PCR method using the primers in Chapter 2.13. To completely avoid the 
expression of L1LONG and L1MIDDLE, pUC19 MnPV L1ΔNT plasmid, which lacks the 31 amino acids 
of N terminal L1 ORF, was constructed by Gibson assembly method described above using primers 
in Chapter 2.13. 
 
3.3 Cell culture 
3.3.1 Maintenance conditions of mammalian cells 
All mammalian cells were grown in Dulbecco’s Modified Eagle’s Medium supplemented 
with 10% fetal calf serum (FCS), 1% Penicillin/Streptomycin and 1% L-glutamine. Hygromycin B 
(125 µg/ml) was added to the culture of human cervical carcinoma cell lines HeLaT as well as 
human embryonic kidney cells 293TT. All cell lines were maintained in the cell incubator at 37°C, 
5% CO2 and 95% humidity. Possible contamination with Mycoplasma was checked by PCR from 
time to time. 
 
For the passaging of HeLa, HeLaT and 293TT cells, cells were washed once with 1 x DPBS 
prior to the addition of 1-2 ml of 0.25% trypsin-EDTA for detachment. Trypsin was inactivated by 
supplemented DMEM medium. Cell pellets were collected by the centrifugation at 1000 rpm for 5 
minutes. For maintenance culture, cells were transferred into culture flasks at a ratio of 1:5 (293TT) 
or 1:15 (HeLa and HeLaT). 
 
For cryoconservation, cell pellet of approximately 2 x 106 cells was resuspended in 1 ml of 
DMEM Cryo Medium into cryotube, which was then wrapped in several layers of tissue papers 
and transferred to -80°C. For longer storage, cells were transferred to liquid nitrogen after one day. 
 
For reactivation of cells, frozen cells were thawed at 37°C and quickly added supplemented 
DMEM medium. The residual DMSO was removed by the centrifugation and cells were then 
seeded to culturing flasks in fresh culture medium.  
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3.3.2 Maintenance conditions of insect cells 
Insect cell lines for VLP production were kindly provided by Prof. Dr. Martin Müller and 
kept at 27°C. Sf9 cells for recombinant baculovirus production were maintained in TNM-FH insect 
medium supplemented with 10% FCS, 1% Penicillin/Streptomycin, 1% L-glutamine and 0.1% 
Pluronic F-68. TN-High-Five cells for baculovirus expression were cultivated in EX-CELLTM 405 
serum-free medium supplemented with 1% Penicillin/Streptomycin and 1% L-glutamine.  
 
For adherent culture, cells were detached by cell scraper and passaged at a ratio of 1:3. For 
suspension culture, 50ml of culture at 1 x 106 viable cells/ml insect cells were seeded with 200ml 
supplemented medium in the spinner flask and cultivated with constant shaking speed of 125-150 
rpm at 27°C. Cell densities were measured by using a standard trypan blue dye exclusion 
procedure. After two or three days, when cell densities reached at 1 x 106 viable cells/ml, cells 
were seeded to the culture flasks according to different amount requirements. 
 
For cryoconservation, cell pellet of approximately 1 x 107 cells was resuspended in 1 ml of 
Cryo Medium (10% FCS, 10% DMSO and 80% TNM-FH supplemented insect medium for Sf9; 
10%DMSO and 90% EX-CELLTM 405 supplemented serum-free medium for High-five) into 
cryotube, which was then wrapped in several layers of tissue papers and transferred to -80°C. For 
longer storage, cells were transferred to liquid nitrogen after one day. 
 
3.3.3 Transfection of expression plasmids 
Mammalian cells were seeded in Petri dishes or Plates one day prior to transfection. Cells 
with confluency of 80% were transfected by using TurboFect transfection reagent according to the 
standard protocol. The ratio of DNA amount and TurboFect transfection reagent was used as 1:2. 
 
3.3.4 Immunofluorescence staining 
First, HeLa cells were grown on coverslips in supplemented DMEM medium to 
approximately 60% confluence. Then, cells were transfected with respective expression L1 
plasmids for 48 hours or infected with respective PsVs (L1LONG-HA +L1SHORT +L2, L1MIDDLE-HA +L1SHORT 
+L2 or L1SHORT +L2) for 30 min. Subsequently, after washing, the cells were fixed in 4% 
paraformaldehyde (PFA) for 30 min at room temperature and washed once again in 1 x PBS. Cells 
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were then permeabilized and blocked in the permeabilization buffer for one hour. The primary 
antibodies were diluted in blocking buffer and applied to the cells for one hour. After washing in 1 
x PBS three times, cells were incubated with specific fluorescein-conjugated second antibodies (1: 
500) and DAPI (1: 10,000) protected from light for one hour. The stained cells were then washed 
several times in 1 x PBS and mounted on glass slides with a drop of Dako Faramount Aqueous 
Mounting Medium. L1 proteins with HA tag were detected by anti-HA antibody and donkey anti-
rat Alexa Fluor 488. L1SHORT protein without HA-tag was detected by mAbs mixture (mAbs 2E2, 
mAbs 2D11 and mAbs 3H8) and goat anti-mouse IgG2a (γ2a) Alexa Fluor 594. For each individual 
experiment, images were analyzed under confocal microscope with the same laser power settings. 
 
3.4 Pseudoviruses production and purification 
3.4.1 Plating and transfection of 293TT cells 
293TT cells (3 x 105 cells/ml) were resuspended and seeded in a 10-cm dish plate with 10 
ml supplemented DMEM one day ahead of transfection. For a normal preparation of pseudoviruses 
production, ten 10-cm dishes were used. Transfection was performed until cells reached 70% - 80% 
confluency by Calcium phosphate transfection. Two tubes were prepared for each transfection: 
one for the DNA/CaCl2/ddH2O mixture, one for the 2 x HBS buffer. 5 µg of each capsid expression 
plasmid and Gaussia/GFP plasmid were mixed with 75 µl 2.5M CaCl2 in ddH2O (750 µl in total). 
The DNA/CaCl2/ddH2O mixture was pipetted to 2 x HBS buffer (750 µl) drop by drop. Then, 
transfection reagent (1.5 ml) was added to each 10-cm dish after the incubation for 30 min at 
room temperature. The cells were incubated for 48h at 37°C, 5% CO2 and 95% humidity without 
changing medium. 
 
3.4.2 Pseudoviruses maturation 
For pseudoviruses production, transfected 293TT cells from 10 dishes were detached by 
pipetting medium up and down several times and were harvested in a 50 ml Falcon tube. Cell 
pellet was resuspended in 1ml DPBS containing CaCl2 and MgCl2 in a 1.5ml Lo-Bind protein tube 
after centrifugation at 1900 rpm for 5 minutes. After another centrifugation at 5000 rpm for 5 min 
at 4°C, pellet was estimated and resuspended in an equal volume of pseudovirus lysis buffer 
(compared to pellet). Cells were lysed for 24 hours on an end-over-end rotator at 37°C. 
 
Methods   
41 
 
3.4.3 Pseudoviruses purification 
Three-step gradient with Iodixanol of 27%, 33% and 39% diluted in 0.8M NaCl/DPBS was 
made and used for pseudoviruses separation. 39% layer was colored with phenol red to make a 
distinction between 39% and 33%. The gradient had to be left overnight at 4°C to soften the edges. 
For the following day, cell lysate was treated with 5M NaCl (17 µl per 100 µl of total volume in 
tube, including pellet and lysis buffer). After centrifugation, the supernatant was collected in a 
new Lo-Bind protein tube and incubated with 2 µl Benzonase for 1 hour at 37°C. After incubation, 
the supernatant was carefully loaded on the top of the Optiprep gradient and balanced with 
DPBS/0.8M NaCl. The pseudoviruses were purified by ultracentrifugation through the gradient at 
37,000 rpm for 5 hours at 16°C with TH641 rotor. The pseudoviruses fractions of each 500 µl were 
collected in Lo-Bind protein tubes by a 0.90 x 40 mm needle puncture on the gradient tube, which 
is one centimeter below the 39% interface line. Fractions were labeled and stored at -80°C. 
 
3.4.4 Infection assay 
HeLaT cells (50 µl, 2.5 x 105 cells/ml) were seeded in 96-well plates 2-5 hours prior to the 
pseudoviruses infection. Pseudoviruses were diluted in 1: 200 and added to the adherent HeLaT 
cells, which were then incubated for 48 hours at 37°C, 5% CO2 and 95% humidity. Gaussia 
luciferase signal in 10 μl of cell medium was measured 15 min after addition of 100 μl mixture of 
Gaussia glow juice and coelenterazine substrate in a microplate luminometer Synergy2 reader. 
 
3.4.5 Pseudovirus-based neutralization assay 
To evaluate the neutralizing capacity of serum from animals, a pseudovirus based 
neutralization assay was carried out. Briefly, 1: 3 serial dilutions from each diluted animal serum 
(1: 60) were made in 96 well plates in duplicate. 40 µl of pseudoviruses with proper dilution were 
mixed with the serial diluted sera at room temperature for 15 min. Next, 50 µl of a density of 
2.5x105 cells/ml HeLaT cells were seeded to the pseudoviruses-serum mixture and followed by two 
days incubation at 37°C, 5% CO2 and 95% humidity. The amount of secreted Gaussia luciferase 
was determined as described in Chapter 3.4.4. 
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Figure 3.4.5: The overview of neutralization assay [108]. Prior to the infection, pseudoviruses are incubated 
with the antibody or serum from animals. The neutralizing capacity is determined by measurement of 
Gaussia luciferase. 
 
3.5 VLP production 
3.5.1 Generation of recombinant baculoviruses 
The generation of recombinant baculoviruses was performed as previously described [100] 
with some modifications. Briefly, recombinant baculoviruses were produced by transfecting Sf9 
cells with recombinant MultiBac bacmids via calcium phosphate precipitation method. At the 
time of transfection, the optimal confluency for adherent Sf9 cells is 75% in 25 cm2 flask. After 
washing, cells were replaced with 1 ml Grace’s Insect Medium supplemented with 1% L-
glutamine. The MultiBac bacmid DNA (1 μg) was diluted in 1 ml transfection buffer and followed 
by dropwise adding to Sf9 cells. After incubation at 27°C for 5 hours, the cells were washed twice 
and then maintained in 10 ml TNM-FH supplemented medium for 6 days. The supernatant was 
used for generation of a high-titer baculovirus stock. Sf9 cells with the density of 2 x 106 were 
seeded in a T25 flask and infected with 1 ml supernatant for virus amplification in next 6 days. 
This step was repeated by passaging increasing supernatant for at least two weeks (3 ml 
supernatant for 1 x 107 Sf9 cells in a 75 cm2 flask and 5 ml supernatant for 2.5 x 107 Sf9 cells in a 
175 cm2 flask). 
 
3.5.2 Recombinant Baculovirus expression test 
Sf9 cells in a 25 cm2 flask were infected by 1 ml supernatant from Passage 2 and incubated 
for 3 days at 27°C. Proteins were extracted and the expression of different L1 isoforms was 
analyzed by Coomassie blue staining and Western blot. 
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3.5.3 VLP production and purification 
TN-High Five cells were cultivated to a density of 2.5 x 106/ml in 250 ml suspension 
culture, which were then pelleted and resuspended in 42 ml EX-CELLTM 405 serum-free medium 
and 8 ml high titer virus stock. The cells were shaken at a low speed for 1 hour at room 
temperature and then incubated within 250 ml final volume of medium for 3 days at 27°C. Cell 
pellets were harvested by centrifugation (3,000 rpm for 10 minutes at 4°C in Sorvall GS-3 rotor) 
and washed in pre-chilled PBS for two times. Dry pellets were resuspended in 10 ml VLP 
extraction buffer containing 200 μl 100 mM PMSF, and then followed by three times sonication. A 
two-step gradient consisting of 7 ml of 40% sucrose on top of 7 ml CsCl solution was prepared. 
Clear cell lysate was obtained by centrifugation (10,000 rpm for 10 min at 4°C in Sorvall F-28/50 
rotor) and carefully loaded onto the top of the CsCl layer. After centrifugation (27,000 rpm for 3 
hours at 10°C in SW-31Ti rotor), the interphase between sucrose and CsCl together with the 
complete CsCl layer was transferred into a Quickseal tube. The fractions were collected in 1 ml 
aliquot after a 16-hour centrifugation at 48,000 rpm at 20°C in a Beckman 70Ti rotor and analyzed 
by Coomassie blue dye and Western blot. Small aliquots from the fraction with the highest and 
lowest protein yield were dialyzed against H2O on a membrane filter and sent for Electron 
microscopy.  
 
3.6 Preparation and analysis of proteins 
3.6.1 Quantification of proteins 
Protein concentrations were measured by Bio-Rad Protein Assay. Briefly, 5 µl of 1: 10 
diluted protein sample with 155 µl H2O were mixed with 40 µl of Bio-Rad Protein Assay solution 
into 96-well plate. BSA serial solutions (0.25 mg/ml to 7.5 mg/ml) were used as the standard curve 
for calculation. The absorptions of protein samples and BSA standard were determined at 595 nm 
in a SPECTROstar Nano plate reader.  
 
3.6.2 SDS-polyacrylamide gel electrophoresis 
Denatured proteins were separated due to their electrophoretic mobility in discontinuous 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), which consists of a 
stacking gel and a separating gel. The SDS gels were made as follows: 
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Separating gel (10% / 12%) Stacking gel (5%) 
0.25 M Tris-HCl, pH 8.8 0.25 M Tris-HCl, pH 6.8 
0.1 % SDS 0.1 % SDS 
10% / 12% Acrylamide/Bisacrylamide 
29:1 
4% Acrylamide/Bisacrylamide 29:1 
0.05% ammonium persulfate 0.05% ammonium persulfate 
0.08% TEMED 0.08% TEMED 
 
After denaturation at 95°C for 5 min, protein samples were supplemented with 5 x SDS 
loading dye. After brief centrifugation, 100-200 µg treated proteins were loaded to the gel along 
with PageRuler Prestained Protein Ladder. The current changed from 80V to 120V until the 
samples reached to the separating gel and stopped until the desired protein separation was 
achieved. 
 
3.6.3 Coomassie blue staining 
The protein bands were directly visualized in the gel by staining with colloidal Coomassie 
G-250 after gel electrophoresis. The gel was washed in water with agitation until the background 
became clear. For longer time storage, the gel was scanned and dried in a vacuum gel dryer for one 
hour at 80°C.  
 
3.6.4 Immunoblotting 
Proteins separated by gel electrophoresis were electrophoretically transferred to a PVDF 
membrane by a wet “sandwich” blotting, which was performed in Mini Trans-Blot®  
Electrophoretic Transfer Cell (Bio-Rad). The wet transfer was assembled according to the 
manufacturer’s instructions and performed 400 mA for 60 min. After blotting, PVDF membrane 
was blocked with 5% milk powder in 1 x TBST at room temperature for 1 hour. The primary 
antibody was added in appropriate dilution with rocking agitation at 4°C overnight. The next day, 
the membrane was washed three times with 1 x TBST and incubated with the secondary antibody 
conjugated with HRP at a 1:10,000 dilution for 1 hour at room temperature, followed by further 
washing. Finally, the specifically bound antibodies were visualized by an HRP-catalyzed enhanced 
chemiluminescent reaction (ECL) and detected by exposure to X-ray film. 
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3.7 Production of Glutathione-S-Transferase (GST)-tag antigen 
The pGEX-4T-3 plasmids with different MnPV late genes (L1LONG, L1MIDDLE, L1SHORT, 
L1ΔNT-31aa and L1ΔNT-41aa) were transformed in E. coli BL21 Rosetta bacteria and cultivated in 
LB medium supplemented with 100 μl/ml ampicillin and 20 μg/ml chloramphenicol at 37°C 
overnight (pre-culture). The early gene E2 vector and empty vector (GST-SV40-tag) was 
transformed in E. coli BL21 and grown in LB medium containing 100 μl/ml ampicillin (pre-
culture). 50 ml of pre-culture was diluted into 1L LB containing the respective antibiotics and 
grown at 37°C until OD600 reached approximately 0.4. The culture was further grown at 25°C until 
OD600 value reached 0.5-0.6 and then induced with 250 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). After certain cultivation at 25°C (6 hours for L1ΔNT-31aa, L1ΔNT-
41aa and GST-SV40-tag; 8 hours for L1SHORT; 18 - 20 hour for L1LONG, L1MIDDLE and E2), the pellets 
were collected by centrifugation for 20 min at 5000 rpm at 4°C in Sorvall GS-3 rotor. The pellets 
were resuspended in 10 ml lysis buffer (1 x PBS for E2 and GST-SV40-tag; buffer L for L1 antigens) 
containing 0.5 ml protease inhibitor cocktail complete and 2 mM DTT. However, for L1 antigens, 
2 mM ATP and 5 mM MgCl2 were added to lysis buffer to facilitate bacterial chaperone 
dissociation. The lysate was sonicated 4 times x 15s with 30s break on ice and then centrifuged at 
14,000 rpm for 1 hour in a Sorvall F-28/50 rotor. For L1 antigens, the homogenized lysate was 
further incubated for 1 hour at room temperature with agitation prior to centrifugation. Finally, 
the supernatant was mixed with one volume of 100% glycerol and store at -20°C. The antigens 
were diluted in a 1: 3 serial dilution in Polysorb Nunc-Immuno plates and titrated by a normal 
GST-ELISA method. Proper dilution of the antigens used for GST-ELISA was determined by 
comparing the OD450 raw value with the old antigen. 
 
3.8 Enzyme-linked immunosorbent assay (ELISA) 
3.8.1 GST-capture ELISA 
The GST-capture ELISA was modified by Schäfer et al for detecting the seroreactivity of 
Mastomys sera [86, 107]. Briefly, glutathione is chemically crosslinked to casein and used to 
capture the fusion protein which contains an N-terminal GST tag. The C terminal SV40 tag is used 
to identify the bond of the completely expressed fusion protein via the monoclonal mouse 
antibody KT3. 200 ng/well glutathione-casein was diluted in 50 mM carbonate buffer (pH=9.6) 
and coated to 96 well polysorp plates overnight at 4°C. The next day, after blocking with casein 
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blocking buffer (180 µl/well) for 1 hour at 37°C, the plate was then incubated respective GST-tag 
fusion protein antigen lysate for 1 hour at room temperature which was purified from bacterial.  
Prior to the serum coating, each Mastomys serum was blocked with a dilution of 1:50 in GST-
SV40-tag casein blocking buffer for 1 hour at room temperature. The GST-SV40-tag fusion antigen 
bacterial lysate was diluted according to the antigen titration as described in chapter 3.7. This 
incubation is essential to get rid of the unspecific reaction between antibodies and bacterial 
proteins or GST/SV40 tags. Afterwards, ELISA plates were washed with 1 x PBST for four times 
and incubated with treated sera for 1 hour at room temperature. After washing, 100 µl/well HPR-
conjugated goat anti-mouse IgG antibody was applied to 96 ELISA plates with a dilution of 1: 
10,000 in casein blocking buffer. After washing, antibodies were quantified colorimetrically by 
incubating with 100 μl/well of substrate buffer for 8 minutes (0.1 mg/ml tetramethylbenzidine and 
0.006 % H2O2 in 100 mM sodium acetate, pH=6). The enzyme reaction was stopped with 50 
μl/well of 1 M sulphuric acid and absorption was measured at a wavelength of 450 nm. The 
reactivity of serum against each antigen was calculated by subtracting the background GST-SV40 
tag value from the respective viral antigen. Each ELISA was repeated at least twice. 
 
Figure 3.8.1: The reaction scheme of GST-capture ELISA. The fusion antigen, which displayed a GST-tag at 
the N-terminal and a SV40-tag at the C-terminal, was expressed in E. coli and captured by glutathione-
casein via its N-terminal GST-tag. The antibodies in Mastomys sera were detected by second antibody 
(HRP-conjugated goat anti-mouse IgG). 
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3.8.2 VLP-ELISA  
VLP-ELISA was used to detect antibodies which specifically bind to the intact surface of 
MnPV VLPs. 100 ng/well purified VLPs were coated in 96 Polysorb plates overnight at 4°C. The 
next day, the plates were blocked with casein blocking buffer (180 µl/well) for 1 hour at 37°C. 
Mastomys sera were diluted 1: 100 in casein blocking buffer and followed by adding 150 µl/well to 
first row of the ELISA plate. 100 µl/well of casein blocking buffer were added to the plates besides 
the first row. A 1: 3 serial dilution was made by transferring 50 µl from the previous row to the 
next row after mixing. After incubation of 1 hour at room temperature, the plates were washed 
with 1 x PBST for four times and incubated with 100 µl/well second anybody (HRP-conjugated 
goat anti-mouse IgG, 1:10,000 diluted in casein blocking buffer). After washing, antibodies were 
quantified colorimetrically by incubating with 100 μl/well of substrate buffer for 8 minutes (0.1 
mg/ml tetramethylbenzidine and 0.006 % H2O2 in 100 mM sodium acetate pH=6). The enzyme 
reaction was stopped with 50 μl/well of 1 M sulphuric acid and the absorption was measured at a 
wavelength of 450 nm. Antibody titer represents the last reciprocal serum dilution above blank. 
 
3.8.3 Denaturation assay 
Denatured VLP-ELISA was performed to identify whether Mastomys sera could react with 
the linear epitopes of MnPV L1SHORT protein. Therefore, several denatured conditions were 
checked whether one can completely disrupt VLPs structure from conformational to linear form. 
For a final protocol, denatured VLPs were obtained by heating in coating buffer (50 mM carbonate 
buffer pH 9.6) and coated to ELISA plates overnight at 37°C. Further steps were carried out 
according to the general VLP-ELISA protocol. The five monoclonal antibodies against MnPV 
L1SHORT (mAb2E2, mAb2D6, mAb2D11, mAb5E5 and mAb3H8) and serum mix (sera from five 
tumor-bearing animals) were used as positive and negative controls for denaturation. 
 
Denatured GST-ELISA was performed to identify whether Mastomys sera could react with 
the linear epitopes of MnPV L1LONG and L1SHORT proteins. The denatured GST fusion antigens were 
obtained by heating in coating buffer and were directly coated to the ELISA plates without casein-
glutathione coating overnight at 37°C. Further steps were carried out according to the general 
GST-ELISA protocol. The five monoclonal antibodies against MnPV L1SHORT (mAb2E2, mAb2D6, 
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mAb2D11, mAb5E5 and mAb3H8) and serum mix (sera from five tumor-bearing MnPV positive 
animals) were used as positive and negative controls for denaturation. 
 
3.9 Epitope mapping 
For linear epitope mapping, L1LONG protein was translated into 15 amino acids (aa) peptides 
with 14 aa peptides overlap in microarray by PEPperPRINT Company. Each array contains two 
identical peptide replicates. For conformational epitope mapping, L1LONG protein was translated 
into 7 aa, 10 aa and 13 aa cyclic peptides with 6 aa, 9 aa and 12 aa overlap. Epitopes were identified 
by the antigen and antibody reaction after L1LONG and L1SHORT positive sera were applied to the 
microarray.  
 
3.10 Mass spectrometry 
The peak fraction of pseudoviruses sample (L1LONG + L1SHORT + L2) were handed over to 
Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH) for Mass spectrometry 
analysis. The samples were loaded to SDS-gel and stained with Coomassie blue. The target protein 
region was excised from the gel, trypsinized and the peptides were analyzed. 
 
3.11 Electron microscopy 
Micrographs were taken by Dr. Karsten Richter and Dr. Michelle Neß ling (DKFZ, 
Heidelberg) with Zeiss EM912 or EM910 electron microscopy.  
3.11.1 Negative staining 
The particles structure of pseudoviruses production and virus like particles (VLPs) 
preparation from different L1 isoforms were visualized by negative staining in electron 
microscopy. Samples were applied on carbon coated grids and stained with 2% uranyl acetate.  
 
3.11.2 Transmission electron microscopy 
The infected Sf9 cells or transfected HeLa cells were seeded on Aklar-punches in 
12 well plates and fixed for conventional Epon-embedding according to a standard 
protocol. Briefly, cells were fixed in chemical fixation solution (4% formaldehyde/2.5% 
glutaraldehyde/1 mM MgCl2 /1 mM CaCl2/100 mM cacodylate-buffer, pH=7.2), followed 
by post fixation in 1% osmium tetroxide, dehydration in 50%, 75%, 100% ethanol and 
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resin-embedding. Ultrathin sections were cut at 60 nm nominal thickness and post stained with 
uranyl and lead citrate. 
 
3.12 Statistical analysis 
Graphs Prism 5.0 was used for data analysis. The Gaussia luciferase signals of each fractions 
were shown in mean ± SEM. Time course of different virial immune responses were shown in 
scatter diagram with mean ± SEM. The significant difference of pseudovirus infectivity between 
“L1S + L2” and “L1L + L1S + L2” group was determined by t tests (and nonparametric tests). 
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4. Results 
The aim of this study is to investigate the role of three isoforms of MnPV major capsid 
protein L1 in the immune evasion during the persistence of viral infection. Firstly, the capsid 
assembly ability of L1 proteins was tested (Chapter 4.1). Secondly, L1 seroreactivity was 
characterized in the naturally infected animals (Chapter 4.2) to study the time course of 
seroconversion, neutralizing capacity and epitope recognition. Moreover, detailed analysis of the 
interaction among different L1 isoforms was investigated (Chapter 4.3). 
 
4.1 Capsid formation of L1LONG, L1MIDDLE and L1SHORT  
The open reading frame (ORF) of MnPV major capsid protein L1 contains three alternative 
translation initiation sites, which are located at nucleotide positions (nt) 5701, 5722 and 5794 in 
MnPV genome, potentially leading to the expression of L1LONG, L1MIDDLE and L1SHORT (Fig. 4.1.1). To 
test the capsid formation ability of these L1 isoforms, virus like particles (VLPs) and pseudoviruses 
(PsVs) were produced in insect cells and 293TT cells, respectively.  
 
 
Figure 4.1.1: MnPV L1 potential open reading frames. L1LONG, L1MIDDLE and L1SHORT start at the ATGs at 
nucleotide positions 5701, 5722 and 5794 in MnPV genome, respectively 
 
4.1.1 VLP production 
The MultiBac baculovirus expression system was used to produce VLPs due to the efficient 
expression of multiple genes from independent cassettes [109-116]. The recombinant 
baculoviruses were produced by transfecting Sf9 cells with recombinant MultiBac bacmids. Then, 
cells were passaged once and examined under microscope to check the morphology. The infected 
cells showed typical morphology of baculoviruses infection, which were opaque, notably bigger in 
size and more granular than non-transfected cells (Fig. 4.1.2 A). The expression of three L1 
isoforms was verified by Coomassie blue staining and Western blot before the infection of TN-
High Five cells with the high titer virus stock. As expected, all L1 proteins were expressed and 
migrated at the predicted sizes (55-60 kDa) in SDS-PAGE gel (Fig. 4.1.2 B). These results indicate 
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successful recombinant baculoviruses generation along with L1 proteins expression in the infected 
Sf9 cells.  
 
 
Figure 4.1.2: MultiBac baculovirus expression system. (A). The infected cells (L1LONG, L1MIDDLE and L1SHORT) 
showed typical morphology of baculoviruses infection, which was different from non-transfected cells 
(negative). (B). The expression of L1LONG, L1MIDDLE and L1SHORT. Proteins were extracted from the 
recombinant baculovirus infected Sf9 cells (Passage 2) and analyzed by Coomassie blue staining and 
Western blot. A pool of sera from five MnPV infected tumor-bearing animals (Serum mix) was used as the 
first antibody for immunoblots. 1. L1LONG; 2. L1MIDDLE; 3.  L1SHORT; 4. Non-transfected. 
 
VLPs were extracted by a two-step density gradient of sucrose and CsCl after 
ultracentrifugation. The quality of the CsCl gradient was monitored by measuring refractive index 
of each fraction at room temperature. A continuous rise of CsCl density was obtained, ranging 
from 1.317-1.527 g/cm3 (Fig. 4.1.3 A). Peak L1LONG bands were detected at approximately 1.419 to 
1.407 g/cm3 density in fraction six and seven (Fig. 4.1.3 B). Fraction five and six (CsCl density 
1.427 to 1.415 g/cm3) contained the most L1MIDDLE (Fig. 4.1.3 C). For L1SHORT, the strongest bands 
were in fraction two, three and five, corresponding to a CsCl density of 1.503, 1.474 and 1.446 
g/cm3 (Fig. 4.1.3 D). 
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Figure 4.1.3: Expression of L1LONG, L1MIDDLE and L1SHORT in each fraction. (A). Refractive index of each fraction. 
The CsCl density of each fraction was determined by refractometer at room temperature. L1LONG (B), 
L1MIDDLE (C), and L1SHORT (D) fractions were analyzed by Coomassie blue staining (upper panels) and Western 
blot (lower panels) using serum mix as primary antibody, which was a pool of sera from five MnPV infected 
tumor-bearing animals. 
 
VLPs formation of three L1 proteins was determined by electron microscope (EM). For 
L1LONG and L1MIDDLE, EM analysis revealed that no individual and uniformly shaped VLPs were 
visualized in fraction 6. However, plentiful irregularly shaped particles with size of 20-50 nm were 
found in the top gradient with lowest density (fraction 11). It was difficult to identify 
substructures such as normal capsomeres, indicating L1LONG and L1MIDDLE were not able to form 
Results   
53 
 
correct VLPs under the chosen production condition (Fig. 4.1.4 A and B). For L1SHORT, highly 
concentrated and spherically shaped particles with size of 45-50 nm or 60 nm were found in 
fraction 2 or 5 respectively, where capsomeres could be clearly observed. The VLPs in fraction 5 
were more homogeneous. In fraction 11, particles with notable capsomeres were also detected (Fig. 
4.1.4 C). These results provide strong evidences for the efficient VLPs formation of L1SHORT.  
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Figure 4.1.4: EM analysis of VLPs formation capacity of L1LONG, L1MIDDLE and L1SHORT. Peak fractions as well as 
the respective fractions with lowest density of L1LONG (A) L1MIDDLE (B) and L1SHORT (C) were analyzed by 
electron microscope.  
 
To exclude the possibility that the lack of particles in L1LONG and L1MIDDLE fractions is due 
to loss of fragile or poorly formed particles during extraction procedures, VLPs formation was 
further examined in the SF9 cells without purification process. The cells were infected with high-
titer recombinant baculoviruses at Passage 3 and fixed for EM analysis. The typical “rod” shape 
baculoviruses with approximate 32 nm diameter and 180 nm to 360 nm length were clearly seen 
in the nucleus of all the observed cells. There were abundant baculoviruses with multiple 
nucleocapsids wrapped in the envelope, which possessed a typical bilayer membrane structure. 
However, there were still some nucleocapsids without envelope (Fig. 4.1.5). Since the genes of 
interest were inserted into the engineered MultiBac baculoviral genome, the recombinant L1 
proteins can be produced along with the baculoviruses in the host cell machineries. Although 
plenty of baculoviruses were found in the nucleus of Sf9 cells, indicating successful expression of 
L1LONG and L1MIDDLE, there were no VLPs observed (Fig. 4.1.5 A and B). On the contrary, high-level 
production of spherically shaped particles with size of approximate 50nm in diameter were 
discovered in the nucleus of L1SHORT expressing cells (Fig. 4.1.5 C).  
 
In conclusion, this chapter suggested that L1LONG and L1MIDDLE derived from the first and 
second ATG hardly induced VLPs formation under the chosen condition. This was not due to the 
purification process, since no particles were found in the Sf9 cells. In contrast, L1SHORT starting 
from the third ATG strongly induced VLPs. 
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4.1.2 Pseudoviruses production 
The minor capsid protein L2 plays an essential role for the virus particles formation and 
stabilization. It forms homotypic interactions with neighbor L2 as well as heterotypic binding 
with L1 molecules [117]. It is reported that including both L1 and L2 into particles production 
may facilitate increased particles yield, capsid stability, infectivity and DNA encapsidation [46, 53, 
118-121]. In order to investigate whether L2 can influence the capsid formation ability of different 
L1 isoforms, different pseudoviruses (PsVs) were produced. PsVs were produced in 293TT cells by 
co-transfection of L1 and L2 codon-modified pGEM-IRES expression plasmids together with a 
reporter plasmid containing GFP/Gaussia luciferase and SV40 origin of replication. The expression 
of three L1 isoforms was identified by immunoblotting, using sera mixed from naturally infected 
tumor-bearing animals as primary antibody. As expected, all L1 proteins were detected at target 
size of 55, 58 and 60 kDa. (Fig. 4.1.6 A). PsVs were then purified by ultracentrifugation through an 
Optiprep (iodixanol) step gradient. The quality and quantity of PsVs were assessed by measuring 
the luciferase signals after infecting HeLaT cells for 48h. In the combinations where only L1LONG 
and L2 or L1MIDDLE and L2 were expressed, no luciferase signals were detectable in any fraction. 
Moreover, no PsV-like particles were observed in these fractions under electron microscope, 
which excludes the possibility that L1LONG and L1MIDDLE with L2 can form non-infectious particles. 
(Fig. 4.1.6 B, C and E). However, the detected luciferase signals and EM analysis revealed that 
L1SHORT with the help of minor capsid protein L2 can efficiently form infectious PsVs (Fig. 4.1.6 D 
and E).  
 
In order to investigate the capsid formation ability of different L1 isoforms in various 
systems, PsVs were produced by using L1 codon-modified pPK-CMV-E3 expression plasmids. This 
vector contains a C-terminal HA-tag which facilitates the detection of the target protein by anti-
HA antibodies. In addition, there was another set of plasmids with stop codon between the gene of 
interest and C-terminal HA-tag. The expression of pPK-L1 expression plasmids with or without 
HA-tag was detected by anti-HA antibodies or serum mix. Three L1 proteins migrated at the 
predicted sizes, but the expression of L1SHORT was much more efficient than that of L1LONG and 
L1MIDDLE (Fig. 4.1.7 A). PsVs was then produced by transfecting 293TT cells with pPK expression 
plasmids without HA-tag. PsVs formation capacity of L1 isoforms was consistent with the results 
from above pGEM-IRES expression system. L1LONG and L1MIDDLE hardly formed PsVs, since no 
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Gaussia signal and no particle was detected (Fig. 4.1.7 B and C). Both infection assay and EM 
analysis suggested that L1SHORT strongly induced PsVs (Fig. 4.1.7 D).  
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Figure 4.1.6: PsVs production via pGEM-IRES expression plasmids. (A). Overview of PsVs production. PsVs 
production is based on the transfection of capsid genes L1 and L2 (codon modified) expression plasmids 
together with a reporter plasmid in 293TT cells. PsVs were harvested by ultracentrifugation through 
Optiprep gradient. The expression of L1 isoforms in 293TT cells was checked by serum mix, which was a 
pool of sera from five MnPV infected tumor-bearing animals. The PsVs infectivity from each combination 
L1LONG + L2 (B), L1MIDDLE +L2 (C) and L1SHORT +L2 (D) was determined by infection of HeLaT cells for 48h, 
after which the Gaussia signal was measured. The experimental data were shown in mean ± SEM from three 
independent experiments. (E). PsVs formation of L1LONG, L1MIDDLE and L1SHORT was checked by EM. The red 
arrow refers to PsVs. 
 
 
Figure 4.1.7: PsVs production via pPK-expression plasmids. (A). The expression of pPK-L1 expression 
plasmids in HeLa cells was checked by Western blot. The serum mix was a pool of sera from five MnPV 
infected tumor-bearing animals. Capsid formation and pseudovirus infectivity of L1LONG (B), L1MIDDLE (C) and 
L1SHORT (D) was checked by the EM and measurement of Gaussia signals as described before. The red arrow 
refers to PsVs. 
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To observe particles formation capacity of L1 isoforms in HeLa cells, cells were transfected 
with pPK-L1 expression plasmids without HA-tag and fixed for EM analysis. No particle formation 
was observed in L1LONG and L1MIDDLE expressing cells (data not shown). However, plenty of particles 
were found in the nucleus of L1SHORT transfected cells and a few particles were discovered in the 
cytoplasm as well (Fig. 4.1.8 A). The darker particles might contain DNA inside and the lighter 
one might be empty (Fig. 4.1.8 D). One intriguing finding is that cells containing particles 
exhibited components of distinct structures. For example, apart from the spherically shaped 
particles, arrays of tubes (T) with similar diameter were exclusive in L1SHORT-transfected cells (Fig. 
4.1.8 A and B). Fiber-arrays (F) and crystalline arrangements (C) were less frequently but regularly 
found in particles-containing cells (Fig. 4.1.8 C and D). In the meantime, cells which harbored 
particles also showed chromatin condensed (Ch) and their nuclei were in pyknotic disintegration. 
Besides, mitochondria were inconspicuous and degraded severely to form potential mitophagy (A), 
which might indicate cells were under stress when producing PsVs (Fig. 4.1.8 A).  
 
Altogether, capsid formation of different L1 isoforms was further confirmed by using both 
pGEM-IRES and pPK expression plasmids during the PsVs production. In line with the previous 
results, only L1SHORT possessed the ability to form infectious viral capsids. The L1SHORT expressing 
cells displayed not only PsVs but also tubes, fiber-arrays and crystalline structures, which were 
absent in non-particles-containing cells.  
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Figure 4.1.8: EM analysis of capsid formation of L1SHORT in transfected HeLa cells. (A). Overall view of L1SHORT 
transfected cells under EM. (B). Particles and arrays of tubes with similar diameter were frequently found in 
L1SHORT-transfected cells. Fiber-arrays (C) and crystalline arrangements (D) were less frequent but regularly 
found in particles-containing HeLa cells. P: Particles; T: Tubes; Ch: Compact chromatin; R: Ribosomes; A: 
Potential mitophagy; F: Fiber-array; C: Crystalline arrangements; e: Empty particles; f: Full particles 
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4.2 Characterization of anti-L1 antibodies in the naturally infected animals 
4.2.1 Time course of seroreactivity against early and late viral proteins 
To investigate the humoral response to cutaneous Mastomys papillomavirus infections, 
especially for the L1 isoforms, a case study was performed by following 60 naturally infected 
animals for the duration of their life. Antibody reactions against capsid proteins L1 (long, middle, 
short, N-terminal peptides) and E2 were examined by glutathione S-transferase (GST)-capture 
ELISA and VLP-ELISA. Sera were collected from animals at different ages (682 sera in total). 
Previously, E2 was identified as an early marker for virus infection, as the responses can already 
be seen at an age of four weeks [86, 122]. The first analysis at 8 weeks after birth revealed E2 
reactivity against virus (mean OD450 = 0.257) and the antibodies responses increased from 36 weeks 
(mean OD450 = 0.347) to 76 weeks (mean OD450 = 0.462) in the late infection stage (Fig. 4.2.1).  
 
 
Figure 4.2.1: Seroreactivity against early viral protein E2. Antibody responses against E2 were measured by 
GST-ELISA and illustrated as scatter diagram using a cut-off of OD450 = 0.2. The OD450 represents the optical 
density at a wavelength of 450 nm. In total 682 sera were analyzed and for each time point the mean ± SEM 
is shown. 
Results   
62 
 
 
Figure 4.2.2: Seroreactivity against late viral protein L1 isoforms. Antibody responses against GST-L1LONG (A), 
L1MIDDLE (B) and L1SHORT (C) fusion proteins were measured by GST-ELISA and illustrated as scatter diagram 
using a cut-off of OD450 = 0.2. The OD450 represents the optical density at a wavelength of 450 nm. (D). The 
immune responses against VLPs were measured by VLP-ELISA and illustrated as scatter diagram using a 
cut-off of titer = 300. In total 682 sera were analyzed and for each time point the mean ± SEM is shown. (E). 
Correlation of GST-L1LONG ELISA with GST-L1SHORT ELISA (n= 682 sera). Each point indicates a serum 
measured by both methods (F). Correlation of GST-L1SHORT ELISA with VLP-ELISA (n= 682 sera). The 
regression line represents a linear regression fit. 
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The MnPV L1LONG seroreactivity of naturally infected Mastomys was detectable at 8 weeks 
(mean OD450 = 0.126) and increased in the late infection stage (mean OD450 = 0.474 at 68 weeks). 
The mean value of the animals at 76 weeks was lower than those at 68 weeks, which was mainly 
caused by the death of some infected animals. The number of animals which showed L1LONG 
responses was 8 of 60 at 8 weeks and increased to 39 of 60 by the end of the study, which indicates 
a propagation of virus infection within the colony (Fig. 4.2.2 A). Moreover, it is noteworthy that 
GST-L1MIDDLE antigen reacted with both positive sera for L1LONG and L1SHORT (Fig. 4.2.2 B). 
Furthermore, serological responses against GST-L1SHORT antigen as well as VLPs derived from 
L1SHORT were detectable after 28 weeks and remained high until 76 weeks. This result indicates 
that anti-L1LONG antibodies in the early infection (from 8 to 20 weeks) did not recognize the 
epitopes on the surface of both GST-L1SHORT antigen and intact VLPs (Fig. 4.2.2 C and D). 
Therefore, there was a complete lack of correlation to the GST-L1SHORT ELISA when the induction 
of the antibodies was detected by the established GST-L1LONG ELISA (Fig. 4.2.2 E). However, since 
only L1SHORT was able to form VLPs, there was a significant correlation between the GST-L1SHORT 
ELISA and VLP-ELISA (P< 0.0001, Fig. 4.2.2 F). This result confirms that the lack of 
reproducibility between GST-L1LONG and GST-L1SHORT ELISA was due to the different properties of 
L1 isoforms.  
 
In summary, analysis of MnPV-infected animals during early infection revealed strong 
serological responses against the MnPV L1LONG protein. The majority of these animals did not 
develop anti-L1SHORT antibodies in their whole life, whereas only few animals (8 of 60) elicited 
L1SHORT responses during the late phase of infection.  
 
4.2.2 Time course of individual seroreactivity against L1LONG and L1SHORT proteins 
To better understand L1LONG and L1SHORT seroconversion, the time course of individual 
seroreactivity among 8 animals showing L1SHORT responses was analyzed. Two major immune 
responses patterns were found among these animals. Pattern 1:  Antibody responses against L1LONG 
and/or E2 occurred in the early time and L1SHORT seroreactivity showed during late infection (four 
animals in total, Fig. 4.2.3 A). Anti-E2 antibodies of three animals (220A, 220D and 230C, see Fig. 
4.2.3 A, lower panel) were slightly positive at the beginning and roughly fluctuated around cut-off 
line, whereas immune responses against L1LONG appeared before 20 weeks and L1SHORT 
seroresponses only arose after 44 weeks. Besides, one animal (221C, see Fig. 4.2.3 A, lower panel) 
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harbored very high E2 responses at 20 weeks and was positive for L1SHORT responses after 68 weeks, 
but it didn’t develop anti-L1LONG antibodies in the whole observation period. Pattern 2: Anti-
L1SHORT antibodies were detectable without any immune responses against E2 and L1LONG at the 
early time points (four animals in total, Fig. 4.2.3 B). Interestingly, E2 responses were negative in 
three animals (220B, 220C and 221A, see Fig. 4.2.3 B, lower panel) in the whole-time frame, which 
indicates a lack of strong virus replication after virus infection. After the development of L1SHORT 
responses at 20 weeks, 225A animal was positive both for L1LONG and E2 starting from 44 weeks. 
 
Figure 4.2.3: Time course of the individual seroreactivity against the viral E2, L1LONG and L1SHORT proteins in 
naturally infected colony. (A). Pattern 1: Seroresponses against L1LONG and/or E2 were firstly developed and 
then L1SHORT seroreactivity appeared later. (B). Pattern 2: L1SHORT seroreactivity was detectable without any 
immune responses against E2 and L1LONG at the early time points. Antibody responses against L1LONG and E2 
were measured by GST-ELISA. The immune responses against L1SHORT were measured by VLP-ELISA. 8 
developed anti-L1SHORT antibodies animals in the whole infection stage were shown (n=88 sera). 
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In order to study the influence of ultraviolet (UV)/immunosuppression on the L1 
seroconversion, individual seroreactivity of four cohorts with different treatments was 
investigated (Table 1). This experiment was done in collaboration with Dr. Julita Mikulec and Dr. 
Daniel Hasche. Animals were fed with a normal diet or the immunosuppressant cyclosporine A 
(CsA) with a concentration (125 mg/kg) starting from the age at 15 weeks. UV irradiation was 
performed with a dose of 450 mJ/ cm2 three times per week. Immune responses against the viral 
proteins E2, L1LONG and L1SHORT were followed up from 8 to 68 weeks. 8 animals from the Group A 
(CsA + UV) were negative for L1SHORT responses until 20 weeks of age. 6 of 8 animals had E2 and 
L1LONG responses in the early time, while another two animals (247.4 and 247.5, see Fig. 4.2.4 A 
lower panel) did not show any responses against E2 and L1LONG in their whole life. 6 animals from 
Group B (CsA) developed anti-E2 and anti-L1LONG antibodies early, but L1SHORT antibodies only 
showed up after 28 weeks (Fig. 4.2.4 B). The appearance of anti-L1SHORT antibodies (36 weeks) in 
the Group C (UV) was later than Group A and Group B. Similarly, 8 L1SHORT positive animals from 
Group C exhibited strong E2 and L1LONG responses during the early phase of infection and 
developed L1SHORT antibodies later (Fig. 4.2.4 C). The three naturally infected animals from Group 
D without any treatment, did not developed L1SHORT responses till 44 weeks (Fig. 4.2.4 D).  
 
Table 1. Overview of the CsA and UV study 
 
n = number of animals; CsA = Cyclosporine A. 
 
In conclusion, in the majority of animals, anti-L1LONG antibodies had arisen early and anti-
L1SHORT antibodies appeared only in late stage of infection. Compare to the naturally infected 
colony without treatment, the groups with CsA diet and/or UV irradiation showed more and 
earlier L1SHORT responses, which might indicate that the balance of the virus infection and 
surveillance of immune system had shifted to facilitate the virus propagation due to the suppressed 
immune system. 
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4.2.3 Neutralizing capacity of anti-L1LONG and anti-L1SHORT antibodies 
Given to the fact that L1LONG and L1SHORT responses appear at different time points, it is of 
importance to analyze whether anti-L1LONG and anti-L1SHORT antibodies have different neutralizing 
capacities. The pseudoviruses used for the neutralization assay were produced by co-expression of 
L1LONG, L1SHORT and L2 humanized genes in 293TT cells. Neutralization assay for all the positive 
L1LONG and L1SHORT sera among 60 naturally infected animals revealed that antibodies directed 
against the MnPV L1LONG protein during early infection were not neutralizing. However, anti-
L1SHORT antibodies, which only appeared late, reacted with the surface epitopes of the intact viral 
capsids and were capable of neutralizing virus (Fig. 4.2.5 A). Therefore, a perfect correlation 
between VLP-ELISA and neutralization assay was revealed (Fig. 4.2.5 B). On the other hand, a 
lack of the correlation between the GST-L1LONG ELISA and neutralizing titer was observed (Fig. 
4.2.5 C). Based on the above results, epitopes identification of anti-L1LONG and L1SHORT antibodies 
was tested to further elucidate the properties of L1LONG and L1SHORT proteins. 
 
Figure 4.2.5: Neutralizing capacity of anti-L1LONG and anti-L1SHORT antibodies. (A). Neutralization assay for all 
positive L1LONG and L1SHORT sera among 60 naturally infected animals (n=294 sera). (B). Correlation of VLP-
ELISA value and neutralizing titer of all positive L1LONG and L1SHORT sera (n=294 sera). (C). Correlation 
between GST-L1LONG ELISA value and neutralizing titer of all positive L1LONG and L1SHORT sera (n=294 sera). 
 
4.2.4 Epitopes characterization of anti-L1LONG and anti-L1SHORT antibodies. 
4.2.4.1 Detection of L1LONG N-terminal responses  
The difference between L1LONG and L1SHORT ORF consists of 31 amino acids (aa) at the N-
terminus. Therefore, to answer the question whether anti-L1LONG antibodies can actually bind to 
the epitopes at N-terminus (NT), immune responses against 31 aa were detected by GST-L1NT 
31aa ELISA among 60 naturally infected animals (n= 682 sera). However, only weak or no 
detectable reactivity (under cut-off line) was observed (Fig. 4.2.6 A). Therefore, seroreactivity 
against extended peptide including 9 aa after the third methionine of L1LONG ORF was tested by 
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GST-L1NT 41aa ELISA among all the L1LONG positive animals (39 of 60 animals, n= 297 sera). 
Compared to the responses against 31 aa, there were significantly increased signals against 41 aa 
(Fig. 4.2.6 B). This result might explain why anti-L1LONG antibodies can react with GST-L1MIDDLE 
fusion protein (see Fig. 4.2.2 A and B), but not with GST- L1SHORT fusion protein and VLPs (see Fig. 
4.2.2 C, D and E). 
 
 
Figure 4.2.6: Seroreactivity against the N-terminal peptides of L1LONG. (A). Immune responses against 31aa at 
the L1LONG N-terminus were tested by GST-L1NT 31aa ELISA among 60 naturally infected animals (n=682 
sera). (B). Immune responses against 41aa at the L1LONG N-terminus were measured by GST-L1NT 41aa 
ELISA among 39 L1LONG positive animals (n=297 sera). Cut off was determined as 0.08 by detection among 
the virus-free animals. 
 
4.2.4.2 Denaturation assay 
To determine the properties of epitopes (linear or conformational) recognized by anti-
L1LONG and anti-L1SHORT antibodies, denaturation assays including VLP-ELISA and GST-L1 ELISA 
were performed. To optimize the VLPs denaturation condition, five monoclonal antibodies (mAb 
2E2, mAb 2D11, mAb 3H8, mAb 2D6 and mAb 5E5) against the MnPV VLPs derived from L1SHORT 
were used as controls. Since mAb 2E2, mAb 2D11 and mAb 3H8 were known to recognize 
conformational epitopes [123], a very high signal against intact VLPs was shown in PBS. However, 
reactivities exhibited by mAb 2D6 and mAb 5E5 which were against linear epitopes were 
generally low under non-denatured condition (in PBS, Table 2). Therefore, a successful 
denaturation would anticipate a completely reversed pattern, where mAb 2D6 and mAb 5E5 
would have increased signals with a lack of reactivity of mAb 2E2, mAb 2D11 and mAb 3H8. 
Different reducing agents including increased pH and addition of SDS and urea were used to 
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disassemble VLPs structure into linear forms, yet all three conformation monoclonal antibodies 
still remained strongly reactive, indicating an incomplete denaturation. Finally, VLPs were diluted 
into denaturation buffers with additional heating at 95°C for 10 mins before coating to the 
immune plates. Here, a successful denaturation of VLPs into linear forms was achieved by heating 
VLPs which were diluted in 50 mM carbonate buffer, indicated by the respectively anticipated 
antibodies reactivities (Red box, Table 2).  
 
Table 2. Testing condition of VLPs denaturation 
 
1 „****” : OD450 > 2;  „***“ : 1 <OD450 < 2;  „**“ : 0.1 < OD450 < 1;  „*“ : 0.05 < OD450 < 0.1;  „-“ : OD450 = Blank.  
2 Mer: 2-Mercaptoethanol.  
3 Red box: The optimal condition for VLPs denaturation. 
 
Furthermore, instead of coating the denatured VLPs at 4°C, increased signals of two linear 
antibodies were achieved after coating at 37°C overnight. Serum mix, which was a pool of sera 
mixed from five naturally infected tumor-bearing animals, also showed strong reactivity in the 
denaturation assay (Fig. 4.2.7 A). All L1LONG and L1SHORT positive sera from 60 naturally infected 
animals were tested in denatured-VLP ELISA (n= 306 sera). Interestingly, VLPs denaturation led 
to the reduction of reactivities of all positive sera, demonstrating that anti-L1LONG and anti-L1SHORT 
antibodies might be directed against conformational epitopes (Fig. 4.2.7 B). 
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Figure 4.2.7: Denatured-VLP ELISA. (A). Five monoclonal antibodies and serum mix served as controls to 
evaluate the denaturation condition. VLPs were diluted in 50 mM carbonate buffer and then heated for 10 
min at 95°C. Instead of coating at 4°C, the denatured VLPs were coated at 37°C overnight. (B). Responses to 
denatured VLPs are shown in OD450 value after the L1LONG and L1SHORT positive sera were diluted 1:20 (n=306 
sera). Cut-off (0.3) was determined by the measurement of sera from virus-free animals. 
 
Similar to the denatured-VLP ELISA, denatured-GST ELISA was performed by heating 
GST-L1LONG and GST-L1SHORT antigens at 95°C for 10 mins and the denaturation efficiency was 
assessed by the above-mentioned five monoclonal antibodies and serum mix. Under non-
denatured condition, three monoclonal antibodies (mAb 2E2, mAb 2D11 and mAb 3H8) against 
conformation epitopes exhibited weak reactivities with GST-L1LONG fusion protein, but a strong 
binding with GST-L1SHORT antigen. Two antibodies (mAb 2E6 and mAb 5E5) recognized linear 
epitopes on both GST L1LONG and L1SHORT fusion proteins. After denaturation, only mAb 2E6 and 
mAb 5E5 remained positive reactivities with denatured GST-L1 fusion proteins (Table 3). The 
L1LONG and L1SHORT positive sera from 40 of 60 naturally infected animals during the whole-time 
frame were tested by this denatured-GST ELISA (n= 142 sera). No seroreactivity of the GST-L1LONG 
and GST-L1SHORT positive sera was detectable, suggesting that anti-L1LONG and anti-L1SHORT 
antibodies were indeed directed against the conformational epitopes (Fig. 4.2.8). 
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Table 3. Optimization of the denatured-GST ELISA 
 
1 „****“ : OD450 > 2;  „***“: 1 <OD450 < 2;  „**“ : 0.1 < OD450 < 1;  „*“ : 0.05 < OD450 < 0.1;  „-“: OD450 = Blank 
 
 
Figure 4.2.8: Denatured-GST ELISA. (A). Denatured GST-L1LONG ELISA (B). Denatured GST-L1SHORT ELISA. 
The structure of the GST- L1 antigens was disrupted by heating at 95°C for 10 minutes in the coating buffer. 
The heated antigens were directly applied to the immune plates and coated at 37°C overnight. L1LONG and 
L1SHORT positive sera from 40 of 60 naturally infected animals were measured (n= 142 sera). 
 
In conclusion, by using denatured-VLP ELISA and denatured-GST L1 ELISA, anti-L1LONG 
and anti-L1SHORT antibodies from naturally infected Mastomys colony were proven to be directed 
against conformation epitopes of viral L1 proteins.  
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4.2.4.3 Epitope mapping of anti-L1LONG and anti-L1SHORT antibodies 
In order to identify the epitopes recognized by anti-L1LONG and anti-L1SHORT antibodies, 
linear epitopes were mapped by synthetic 15-mer peptides of L1LONG ORF with a 14 aa overlap in 
microarray. Incubation of the synthetic peptides, microarray with serum samples as well as 
secondary antibodies gave rise to spot patterns indicating identified epitopes. Here, only three 
linear epitopes candidates (ITGHPLY, DYLGMSK and KRSLPASRN) were detected from serum 
mix (positive control), obtained from tumor-bearing animals (Fig. 4.2.9 A and B). No epitope was 
tested from L1LONG and L1SHORT positive sera by this assay (Fig. 4.2.9 A). Since anti-L1LONG and anti-
L1SHORT antibodies were all thought to be directed against conformational epitopes (see Chapter 
4.2.4.2), L1LONG ORF was translated into 7 aa, 10 aa and 13 aa cyclic peptides with maximum 
peptide overlaps of 6 aa, 9 aa and 12 aa. The cyclic peptides with stable thioether bonds were 
synthesized by thioether formation between a C-terminal cysteine side chain and the 
bromoacetylated N-terminus to mimic the conformational epitopes. However, again no epitope 
was successfully mapped (data not shown), which might be due to the limitation of this technique 
and complex situation of the conformation or discontinuous epitopes of anti-L1LONG and anti-
L1SHORT antibodies. 
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Figure 4.2.9: Epitope mapping of anti-L1 antibodies. (A). Identification of linear epitopes for anti-L1 
antibodies. L1LONG ORF was translated into 15 aa peptides with 14 aa peptide overlap. Epitopes were 
identified by the antigen and antibody reaction after L1LONG and L1SHORT positive sera and serum mix were 
applied to the microarray. (B). The intensity plots with three linear epitopes candidates. The spot intensities 
of three linear epitopes identified from serum mix were shown.  
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4.3 The association of L1LONG, L1MIDDLE and L1SHORT proteins 
4.3.1 Capsid formation of L1LONG and L1MIDDLE with the help of L1SHORT and L2   
In order to investigate whether L1LONG protein is present in capsids of produced PsVs, mass 
spectrometric analysis was carried out. The quality and quantity of PsVs was examined by electron 
microscopy and infection assay prior to mass spectrometry (Fig. 4.3.1 A). The GST-L1 LONG antigen, 
which was expressed in the bacteria, was used as a reference to check the N-terminal peptides. 
The PsVs sample and GST-L1 LONG antigen were stained with Coomassie blue dye in SDS-PAGE gel. 
The target proteins were excised from the gel, trypsinized, and the peptides were analyzed (Fig. 
4.3.1 B). Mass spectrometry analysis identified a long N-terminal peptide (HCPDAGVSAGISI 
FQMAYWLPNNQ) in the GST-L1LONG antigen lysate. Even though many peptides derived from 
the L1SHORT ORF were detected, no N-terminal peptide was found in PsVs sample by TOP-down 
proteomics. However, one peptide (TIIYTR) from the L1LONG N-terminus was detected by parallel 
reaction monitoring (PRM), a method which provides benefits in high resolution and high mass 
accuracy quantitative proteomics. (Fig. 4.3.1 C). This result suggests that L1LONG together with 
L1SHORT and L2 might be able to form the viral capsids or L1LONG protein might interfere with 
capsid formation in the presence of L1SHORT.  
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Figure 4.3.1: Mass spectrometry analysis of PsVs production. (A). The quality and quantity of PsVs was 
evaluated by EM and infection assay. PsVs were produced by co-transfection of L1LONG, L1SHORT and L2 
expression plasmids in 293TT cells. The infectivity data were shown in mean ± SEM of one representative 
experiment, from which infectivity of each PsVs fraction was repeated four times. (B). GST-MnPV-L1LONG 
antigen and fraction 5 from representative PsVs production shown in (A) was stained by Coomassie blue dye. 
The boxed regions were cut for further trypsin digestion and Mass spectrometry. (C). Peptides analysis of 
the GST-MnPV-L1LONG antigen and PsVs derived from L1LONG, L1SHORT and L2 combination. The inverted 
triangles represent methionine. The identified N-terminal peptides were marked in black squares. Identified 
peptides were marked in yellow. Peptides with residues modification (deamidation, oxidation and 
carbamidomethyl) were marked in green. 
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In order to determine whether both long and middle proteins can form capsids with the 
assistance of L1SHORT, the different proteins were analyzed by immunofluorescence staining of 
PsVs-infected HeLa cells. Since there was no antibody available to recognize N-terminal peptides 
of L1LONG, plasmids expressing L1LONG and L1MIDDLE fused to an HA-tag at the C-terminus (pPK-
L1LONG-HA and pPK-L1MIDDLE-HA) were used for PsVs production. For the detection of L1SHORT 
protein (without HA-tag), a mixture of three monoclonal antibodies (mAbs) against 
conformational epitopes on MnPV VLPs (mAbs 2E2, mAbs 2D11 and mAbs 3H8) were used, 
according to a colocalization of HA and mAbs signals when L1SHORT-HA fusion protein was 
checked by immunofluorescence staining (Fig. 4.3.2 A). This result indicates that HA-tag at the C-
terminus might do not change the capsid formation of L1 protein. Moreover, there was no cross 
reaction between the anti-HA antibody and mAbs mixture when L1SHORT (without HA-tag) and 
L1LONG-HA fusion proteins were detected in transfected cells (Fig. 4.3.2 B and C). 
 
 
Figure 4.3.2: Detection of L1 proteins by anti-HA antibody and monoclonal antibodies mixture (mAbs 2E2, 
mAbs 2D11 and mAbs 3H8). HeLa cells were fixed and processed for the detection of DAPI (blue), HA 
(green) and mAbs (red) 48h after transfection of pPK-L1SHORT-HA plasmid (A), pPK-L1SHORT plasmid (B) or 
pPK-L1LONG-HA plasmid (C). The L1LONG-HA fusion protein was detected by anti-HA antibody and donkey 
anti-rat Alexa Fluor 488. The L1SHORT protein was detected by mAbs mixture and goat anti-mouse IgG2a (γ2a) 
Alexa Fluor 594. 
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HeLa cells were incubated with respective PsVs (L1LONG-HA +L1SHORT +L2, L1MIDDLE-HA 
+L1SHORT +L2 or L1SHORT +L2) for 30 min and fixed for indirect immunofluorescence staining with 
anti-HA antibody or mAbs mixture. L1SHORT was shown to be present in the PsVs capsids, 
indicated by the mAbs mixture staining on the surface of infected cells. However, no HA signal 
was observed, demonstrating that L1LONG-HA and L1MIDDLE-HA fusion protein did not take part in 
the capsid formation even with the help of L1SHORT and L2 proteins (Fig. 4.3.3 A). Meanwhile, 
since a reporter plasmid containing Gaussia/GFP was used for DNA encapsidation during the PsVs 
production, there might be a possibility that GFP is expressed in the cells after PsVs infection. To 
exclude the endogenous background fluorescence caused by the above reason, PsV-infected HeLa 
cells were fixed and then directly tested by confocal microscope with the same parameter settings 
(Fig. 4.3.3 B).  
 
Taken together, in spite of adding L1SHORT and L2, L1LONG and L1MIDDLE still lack the ability 
to form capsids during PsVs production. Therefore, the detection of the N-terminal peptide of 
L1LONG in PsVs sample (Fig. 4.3.1) might suggest that L1LONG interferes with the capsid formation.  
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Figure 4.3.3: Detection of L1LONG, L1MIDDLE and L1SHORT protein in PsVs-infected HeLa cells. (A). Cells were 
infected with respective PsVs (L1LONG-HA +L1SHORT +L2, L1MIDDLE-HA +L1SHORT +L2 or L1SHORT +L2) for 30 min 
and fixed for further DAPI (blue), HA (green) and mAbs (red, mAbs 2E2, mAbs 2D11 and mAbs 3H8) 
staining. (B). Negative controls for the experiment in (A). Uninfected HeLa cells were fixed for 
immunofluorescence staining and then checked by confocal microscope. Additionally, PsVs-infected cells 
were fixed and directly examined under microscope to exclude background signals. The L1LONG and L1MIDDLE 
proteins with HA tag were detected with anti-HA antibody and donkey anti-rat Alexa Fluor 488. L1SHORT 
was detected with mAbs mixture and goat anti-mouse IgG2a (γ2a) Alexa Fluor 594. 
 
4.3.2 Interference of L1LONG and L1MIDDLE proteins with capsid assembly 
To investigate whether L1LONG protein could interfere with the capsid forming process, a 
competition assay was performed by the co-expression of L1LONG in the normal PsVs production 
(L1S + L2). PsVs infectivity was compared between these “L1S + L2” and “L1L + L1S + L2” groups. 
To ensure equal amounts of plasmids used in these two settings, pGEM-IRES vector without insert 
was co-transfected with expression plasmids in “L1S + L2” group. PsVs from both groups were 
produced and purified at the same time under the same condition to avoid an experimental bias. In 
comparison to the average of Gaussia signals of all the collected fractions, the PsVs infectivity of 
“L1S + L2” group was significantly higher than that of “L1L + L1S + L2” group (p = 0.0014), which 
indicates that less infectious particles were formed when L1LONG protein was expressed in the cells 
(Fig. 4.3.4).  
 
Figure 4.3.4: Comparation of PsVs infectivity between “L1S + L2” and “L1L + L1S + L2” group. 5 µg of each 
expression plasmid (L1LONG, L1SHORT and L2) was used for the PsVs production in “L1L + L1S + L2” group. 5 
µg of pGEM-IRES vector without insert together with 5 µg of each expression plasmid (L1SHORT and L2) were 
used for PsVs production of “L1S + L2” group. The respective PsVs infectivity was determined by the 
average of Gaussia signals of all the collected fractions. The experimental data are shown in mean ± SEM 
from three independent experiments. **p < 0.01, p= 0.0014. 
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To analyze the intracellular distributions of the different L1 isoforms, HeLa cells were 
transfected with different expression plasmids for 48h and processed for indirect 
immunofluorescence staining. The L1LONG-HA and L1MIDDLE-HA fusion proteins were detected by 
anti-HA antibody, whereas L1SHORT protein was detected by mAbs mixture as described before (see 
Chapter 4.3.1). The L1LONG-HA and L1MIDDLE-HA fusion proteins were found to be distributed in 
the nucleus. Due to the high expression levels, some cytoplasmic staining was also found (Fig. 
4.3.5 A and B).  However, the majority of the L1SHORT protein exhibited smooth nuclear rim 
staining in the cells (Fig. 4.3.5 C).  
 
Figure 4.3.5: Localization of L1 proteins. HeLa cells were fixed and processed for the detection of DAPI 
(blue), HA (green) and mAbs mixture (red, mAbs 2E2, mAbs 2D11 and mAbs 3H8) 48h after transfection of 
pPK-L1LONG-HA plasmid (A), pPK-L1MIDDLE plasmid (B) or pPK-L1SHORT plasmid (C). The L1LONG and L1MIDDLE 
proteins with HA tag were detected by anti-HA antibody and donkey anti-rat Alexa Fluor 488. The L1SHORT 
protein was detected by mAbs mixture and goat anti-mouse IgG2a (γ2a) Alexa Fluor 594. 
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To test a putative interaction with L1SHORT, pPK plasmids expressing L1LONG and L1MIDDLE 
were co-transfected with pPK-L1SHORT plasmid in HeLa cells. The co-expression with L1SHORT 
revealed a strong effect on L1LONG and L1MIDDLE localization. As shown in Fig. 4.3.6, a colocalization 
can be observed, where L1LONG-HA and L1MIDDLE-HA fusion proteins can now be found together 
with L1SHORT in the cytoplasm or at the nuclear rim. 
 
 
Figure 4.3.6: Colocalization of L1 proteins in the HeLa cells. Cells were fixed and processed for the detection 
of DAPI (blue), HA (green) and mAbs mixture (red, mAbs 2E2, mAbs 2D11 and mAbs 3H8) 48h after co-
transfection of pPK-L1LONG-HA plasmid and pPK-L1SHORT plasmid (A), or pPK-L1MIDDLE plasmid and pPK-
L1SHORT plasmid (B). The L1LONG and L1MIDDLE proteins with HA-tag were detected by anti-HA antibody and 
donkey anti-rat Alexa Fluor 488. The L1SHORT protein was detected by mAbs mixture and goat anti-mouse 
IgG2a (γ2a) Alexa Fluor 594. 
 
In conclusion, competition assays in PsVs production revealed that the capsid formation 
process by L1SHORT might be inhibited in the presence of L1LONG protein. A possible direct 
interaction with L1SHORT is further inferred by changes in the intracellular localization when 
L1LONG or L1MIDDLE is co-expressed together with L1SHORT.  
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5. Discussion 
5.1 Alternative initiation translation codons of MnPV L1 protein 
Alignment of translation initiation codons for PVs major capsid protein L1 revealed that 
cervical carcinoma-associated types (HPV 16, 18, 45, 52, 54, 58) possess additional ATGs, while 
non-cancer-causing types do not (HPV 3, 7, 6b, 11, 13, 42) [32]. Notably, similar to high-risk HPV 
types, MnPV L1 ORF also contains three ATG codons at its N-terminus (Fig. 4.1.1). According to 
several following ribosome scanning mechanisms, these different L1 isoforms might be formed. (1). 
40S ribosomal subunits are recruited to the capped 5’-end of mRNA and move linearly until the 
first AUG is found, whereupon translation initiation can start [124]. It is believed that the 
initiation/scan-through ratio depends on the nucleotide context in the vicinity of the AUG. Once 
the context does not match with the Kozak sequence, a proportion of scanning complexes may be 
inclined to skip this AUG and initiate translation at the next AUG (so-called leaky scanning 
mechanism) [125, 126]. (2). Alternatively, after termination of a small reading frame, some 
ribosomes remain attached to the mRNA and resume scanning in 3’ direction, regaining 
competence to reinitiate translation at a downstream AUG codon (so-called ‘‘termination-
reinitiation mechanism’’) [127, 128]. (3). A third mechanism exists that enables a cap-independent 
initiation through the internal ribosome entry sites (IRES), which has been proven in several 
cellular genes, hepatitis C virus and picornaviruses [129]. (4). Another translation initiation 
mechanism (so-called ‘‘ribosomal shunting’’) relies on cap-dependent discontinuous scanning. 
Here, ribosomes first bind to the 5’ end of mRNA and start scanning for a short distance, then 
bypass the intervening sequences and initiate translation at a downstream site. This has been 
observed in adenovirus, Sendai virus, HPVs, cauliflower mosaic virus and others [130-133]. Based 
on these different possible mechanisms, there is a high likelihood that several different MnPV L1 
isoforms can be translated from a transcript containing multiple in-frame AUGs.  
 
Using in vitro expression systems, the expression of L1LONG, L1MIDDLE and L1SHORT in insect 
cells as well as in mammalian cells was confirmed in SDS-PAGE gels with their corresponding 
sizes (Fig. 4.1.2, Fig. 4.1.6 and Fig. 4.1.7). However, the short L1 mRNA had significantly higher 
translation efficiency than L1LONG and L1MIDDLE starting from the first and second ATG, respectively. 
Similarly, it is also reported that HPV58 L1SHORT proteins were more abundant than L1LONG in 
keratinocytes after transient transfection with L1 expression constructs. This might be due to a 
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stem-loop structure with high ΔG value downstream of the first AUG codon in its mRNA 
secondary structure, which might prevent efficient binding of ribosomes to the mRNA thus 
blocking the long L1 translation [134]. Therefore, this might also be the case for MnPV L1 
expression. 
 
Analysis of the assembled MnPV transcriptome showed that there is a major 
monocistronic transcript which codes for L1SHORT, driven by the late promoter. However, L1LONG 
and L1MIDDLE are potentially encoded by other polycistronic mRNA isoforms along with the early 
and late genes which are controlled by the early promoter [135]. The Kozak consensus sequence 
for L1LONG  and L1MIDDLE ORF is equivalent or superior to the short L1 isoform in the polycistronic 
transcripts, as has been previously described for HPV 16, 18, 45, 52, 54, 58 [32]. There might be an 
expression preference for L1LONG and L1MIDDLE compared to the short version from such transcripts. 
The late gene expression of mucosal high-risk HPV such as HPV16 and 31 only occurs in the 
differentiated uppermost granular layer, but cutaneous HPVs such as HPV1 and 63 start capsid 
proteins synthesis much closer to the basal layer [136, 137]. Therefore, it is likely that L1LONG is 
translated from a polycistronic mRNA which carries several ORFs of viral proteins driven by an 
early promoter during the early infection. It is therefore tempting to speculate that there might be 
a switch from long to short L1 expression during the viral infection stage, which could be caused 
by the early and late viral promoter switch during different infection phases or a change in the 
ratios of respective transcripts. Seroreactivity of MnPV-infected animals showed that strong 
MnPV L1LONG immune responses, which had no reactivity with the intact capsids, occurred during 
the early infection period (Fig. 4.2.2). This indicates that the expression of L1LONG might be 
achieved in the early infection stage in vivo. The expression of L1LONG in the early infection phase 
elicits a production of antibodies that are not neutralizing, which might be due to the fact that 
L1LONG hardly induces capsid formation (Chapter 4.1). The functional antibodies that are capable of 
neutralizing virus might appear after a switch to massive transcript expression towards L1SHORT at 
the late infection stage, when virus capsids are efficiently assembled. With this strategy, virus 
might escape the host defense systems by avoiding the neutralizing antibodies at the beginning of 
viral infection, thus facilitating a productive infection. This immune evasion mechanism will be 
discussed in detail in Chapter 5.3. 
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5.2 Different capsid formation ability of L1LONG, L1MIDDLE and L1SHORT  
The different capsid formation ability of MnPV L1 isoforms was verified by various cell 
systems including VLPs production in insect cells and PsVs production in 293TT cells (Chapter 
4.1). One difference between these two systems is that minor capsid protein L2 is incorporated 
into PsVs to mimic the native viral capsids, which might facilitate capsid formation [119, 138]. An 
indispensable L1 intercapsomeric disulfide bond for virion stability is formed between cysteines 
426 in the C-terminal arm and cysteines 171 on a subunit of neighboring capsomere. This bond is 
only formed in cell lysis in an oxidizing environment during intracellular assembly [47]. Therefore, 
an extra PsVs maturation step is performed by incubation of the cell lysate at 37°C overnight for 
the strengthening of such disulfide bonds between the neighboring L1 molecules, thus supporting 
the capsid stability and solubility [139]. However, even with these advanced procedures, the 
capsid assembly of different L1 isoforms still remained the same in both systems:  
 
No particles with classic capsomeres subunits were identified from L1LONG and L1MIDDLE 
indicating that both proteins hardly self-assemble into correct VLPs. Moreover, even with the 
help of L2, these proteins still lack the ability to accurately assemble viral particles. In contrast, 
L1SHORT strongly induced uniformly shaped VLPs with typical capsomeres as well as infectious 
particles during PsVs production (Fig. 4.1.4 - Fig. 4.1.7). A similar situation was reported in several 
studies. Only the recombinant HPV16 L1 protein derived from the second initiation codon (5637 
nt) was able to produce high quantities of VLPs [41, 140] [141]. However, VLPs production was 
unsuccessful when the first initiation codon (5559 nt) was used [142, 143]. The self-assembly 
ability of VLPs derived from different MusPV L1 ORFs was previously investigated in the 
baculovirus expression system. MusPV L1 protein starting from the second ATG hardly folded 
into VLPs, whereas the L1 proteins derived from the 3rd and 4th translation initiation codon 
successfully generated correct VLPs that were able to elicit neutralizing antibodies [33]. These 
results indicate that capsids efficiently form only when the translation of L1 is started at the 
correct methionine. It is reported that capsids can only be successfully assembled from L1 protein 
in which the methionine is located close to a consensus Wx7YLPP motif [33]. In the MnPV L1 
ORF, only the methionine of L1SHORT is close to this motif. Therefore, it is obvious that the N-
terminal residues of MnPV L1 play a critical role for the capsid assembly, because the addition of 
residues leads to insufficient capsid formation.  
Discussion   
85 
 
Chen et al. demonstrated that N-terminally truncated L1 protein favors formation of a 
small VLP (12-pentameric icosahedral particle, T = 1) instead of a T = 7 icosahedral lattice, 
indicating an essential role for the N-terminal peptides in the intercapsomeric binding [36]. 
Furthermore, residues 1 - 20 of the HPV16 L1SHORT N-terminal moiety are thought to form a  β-
hairpin structure and serve as interpentameric contacts to fill the gap in the virus capsid shell, 
which is important for maintaining the capsid stability [35]. Therefore, it is reasonable to assume 
that the different capsid assembly abilities of L1LONG and L1MIDDLE might be due to alterations in 
protein structure caused by the N-terminal residues. In the naturally infected M.coucha colony, 
anti-L1LONG antibodies were shown to be directed against the conformational epitopes of the 41 
amino acids and were unable to recognize the 31 amino acids from the N-terminus (Fig. 4.2.6). 
Presumably, the additional N-terminal arm might form a loop that completely changes the 
functional structure of L1 protein. Since no capsomeres-like structures were observed following 
L1LONG and L1MIDDLE VLPs production, this loop might prevent the binding between pentamers or 
even make it difficult to form capsomeres, thus avoiding complete assembly of the closed 
icosahedral particles.  
 
To further investigate the capsid assembly capacity of different L1 isoforms, capsid 
formation was examined in HeLa cells. Viral particles as well as specific structures such as tubes 
were exclusively observed in L1SHORT expressing cells (Fig. 4.1.8), while absent in the L1LONG and 
L1MIDDLE transfected cells. The tubular structures have been also found in human and rabbit 
papillomavirus wart extracts [144], HPV 33 VLPs extract [145] as well as in murine polyomavirus 
(PyV)-infected tissue culture cells [146, 147]. Besides, it is reported that tubular structures were 
adjacent to clusters of assembled virions in the nucleus of PyV-infected mouse fibroblasts [148]. 
One hypothesis on the function of these tube structures is that capsomeres firstly polymerize into 
tubes and the interior of tubular structures is then traversed by the viral chromatin. Finally, the 
icosahedral particles are shed from the ends of this structure. Consistent with previous studies for 
human polyomavirus JC [149, 150], tubes in particle-containing cells were dominantly found near 
the periphery of cellular compact chromatin, indicating that capsid proteins and DNA might 
interact in a coordinated manner to form viral particles. Therefore, the specific structures in 
MnPV particle-containing cells suggest that the virion assembly occurs at specific intracellular 
sites which might function as virus factories [151, 152]. This result might also shed light on the 
different capsid formation ability of L1 isoforms. The N-terminal residues of L1 protein cause the 
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inability of capsid formation, indicated by the fact that only L1SHORT-transfected cells harbor this 
specific virus machinery.  
 
5.3 Immune responses in the naturally infected animals 
The most effective strategy to escape from host surveillance is that viruses become 
invisible to the host immune system, which inhibits the triggering of effective antiviral responses, 
such as the production of neutralizing antibodies. Raising neutralizing antibodies with high titer 
against surface epitopes of virions has long been considered the primary mechanism of protection, 
since these antibodies can inhibit virus infection by the association with viral particles. Many 
neutralizing antibodies can abrogate viral particles attachment to the cells prior to the entry 
process. Some antibodies can also interfere with the interplay between virus and cellular 
endocytic machinery after attachment. Moreover, after viral endocytosis, neutralizing antibodies 
also have been shown to have negative effects on viral internalization, uncoating, trafficking, 
nuclear import and virion transcriptase activity [153-161]. In the whole Mastomys colony, 44 of 
60 naturally infected animals in total developed antibodies against virus proteins including E2, 
L1LONG and L1SHORT during their life (Fig. 4.2.1 and 4.2.2). However, only 8 animals produced 
conformation-dependent neutralizing anti-L1SHORT antibodies (Fig. 4.2.3 and 4.2.5). This might 
represent an immune escape, since non-neutralizing antibodies (anti-L1LONG antibodies) are 
dominant in the early infection stage. In other words, once animals become infected with MnPV 
shown by strong E2 seroresponses, L1LONG seroreactivity is immediately elicited which however 
lacks the ability to prevent virus infection. The absence of protective antibodies in the early 
infection phase might facilitate virus replication and virions escape from recognition by the 
immune system. These results are consistent with the finding that the HPV16 L1 neutralizing 
antibodies developed late (8 and 9 months after the first HPV positive DNA detection) [77, 162] 
[163]. Besides, this virus evasion scenario is also in line with past observations in JC polyomavirus 
where mutations in the surface loops of the major capsid protein VP1 might enable the virus to 
avoid antibody-mediated neutralization [164]. 
 
As shown in Fig. 4.2.3, two major patterns of immune responses can be found among 
LSHORT seropositive animals. L1LONG and/or E2 seroresponses occurred during the early time and 
L1SHORT immune responses showed later (Pattern 1). This pattern perfectly fits to an immune 
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evasion mechanism as described before. Conversely, L1SHORT immune responses were detected 
without L1LONG and E2 seroresponses at the early time points (Pattern 2). This pattern can be 
explained as follows: 
 
No E2 seroresponses in the early time after infection might indicate that the majority of 
the original virions would be presented to the dendritic cells for stimulation of cell-mediated 
immunity, which are finally eliminated by the T cells without virus genome replication [165, 166]. 
L1SHORT seroreactivity might be caused by infection of virions that are not completely cleared by 
the cellular immunity. After exposure of viral surface epitopes and with the help of T helper cells 
through CD40, B cells eventually differentiate into plasma cells that generate antibodies against 
conformational epitopes of L1SHORT [167]. This process is similar to VLPs vaccination against HPV, 
which results in the production of the antibodies against conformational epitopes on the surface of 
virial capsids after injection [168]. This pattern also supports the mentioned immune escape 
hypothesis that once anti-L1SHORT antibodies (against VLPs) are developed without virus 
replication (no E2 and L1LONG seroresponses) in the early stage, they can efficiently inhibit the 
propagation of virus infection, indicated by the lack or delay of E2 seroresponses in the whole-
time frame. In accordance with findings previously reported, patients with development of 
antibodies against HPV16 VLPs in the early stage were found to be less likely to develop a 
recurrence or die of  invasive cancer [169].  
 
Humoral immune responses against viral proteins under immunocompetence and systemic 
immunosuppression (CsA diet, UV irradiation) were additionally measured to investigate the 
impact of different immune conditions on L1 seroconversion (Fig. 4.2.4). Only few animals (3 of 8) 
developed anti-L1SHORT antibodies in the immunocompetent control group, which is the same 
situation in the naturally infected colony without any treatment (8 of 60). Compared to the 
control group, there were more animals exhibited L1SHORT seroresponses in the CsA and UV 
treatment groups, which can be explained by the following reasons. CsA as an immunosuppressive 
drug is able to suppress T cells activity [100, 170, 171]. Furthermore, the exposure of skin to UVB 
with wavelength of 290-320 nm leads to alteration of the local and systemic immune system by 
changing the epidermal cytokine profile, hereby inhibiting infection clearance by suppressing 
cellular immunity [172-175]. Since PVs infection can be cleared by T cells, the massive production 
of anti-L1SHORT antibodies suggest that virions are largely produced in the late infection phase due 
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to the immunosuppression condition by CsA and UV treatment. The escape from neutralization in 
the early infection period might increase the efficacy of virus propagation under circumstances 
where T-cell mediated immunity is impaired. Therefore, the status of immune system is essential 
for immune recognition and responses. 
 
5.4 Characterization of anti-L1LONG and anti-L1SHORT antibodies 
Anti-L1LONG antibodies in the early infection stage did not react with either GST-L1SHORT 
antigen or VLPs, and anti-L1SHORT antibodies failed to recognize epitopes on GST-L1LONG fusion 
protein (Fig. 4.2.2 and Fig. 4.2.3). As already demonstrated, correct capsid formation can only be 
induced by L1SHORT rather than L1LONG (Chapter 4.1). These results suggest that L1LONG and L1SHORT 
antibodies recognize different epitopes on their corresponding antigens, which might be caused by 
the different proteins structures presented to immune system. Anti-L1LONG antibodies might bind 
to specific epitopes at the N-terminus (Fig. 4.2.6). Probably, a loop formed by 41 amino acids from 
the N-terminal peptide is the dominant region that is exposed on the exterior surface of protein 
that fails to form correct capsid but easily identified by the immune system. Especially, 9 amino 
acids after the third methionine of L1LONG N-terminus would contribute to epitope recognition of 
anti-L1LONG antibodies. Moreover, since serum contained a mixture of polyclonal antibodies and 
some positive L1LONG sera did not react with 41 amino acids, anti-L1LONG antibodies might be also 
directed against epitopes completely within the short ORF, which are not exposed on the surface 
of the normal capsids. Overall, all the above reasons can explain why anti-L1LONG antibodies 
cannot neutralize virus due to the fact that neutralizing antibodies only recognize epitopes on the 
intact viral capsids. This is also a crucial aspect to explain how viruses evade the host defense 
system by producing non-neutralizing antibodies in the early infection phase. 
 
Since anti-L1SHORT antibodies are conformation-dependent neutralizing antibodies (Chapter 
4.2.3 and 4.2.4), they might be directed against epitopes on the loops extending toward the outer 
surface of capsomeres as well as C-terminal arm. It has been reported that passive immunization of 
sera from MnPV VLPs-vaccinated to naturally infected animals prevents viral infection, indicating 
that neutralizing anti-L1SHORT antibodies are sufficient for protection [100]. There are several 
neutralizing antibodies types to elucidate the different mechanisms for neutralization. For 
example, BPV mAb#9 can bind to the pentavalent and hexavalent capsomeres, thus blocking the 
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virus binding to the host cells. The main neutralizing function of BPV mAb#5B6 might be the 
prevention of virus capsid internalization rather than the significant inhibition of the viral 
binding to the cells surface. This might be due to the fact that mAb#5B6 can only bind 
monovalently and bivalently to the hexavalent capsomeres sides [176]. The HPV11 H11.B2 mAb is 
directed against epitopes within the center of capsomere, which coincides with L2 location on the 
capsid [177]. The HPV16 H16.V5 has a higher affinity to the hexavalent capsomeres than the 
pentavalent capsomeres and is able to recognize epitopes (17 residues) located on the five exterior 
flexible loops (BC, DE, FG, EF, and HI loop) from two neighboring L1 molecules [178]. HPV16.U4 
is mapped to the intercapsomeric C-terminal region of L1 and blocks the binding to the cell 
surface rather than the extracellular matrix (ECM) [156] [179]. Therefore, the elicited anti-L1SHORT 
antibodies in the naturally infected colony might also recognize either of the mentioned 
conformational epitopes, thus exhibiting neutralization. Even though there are several 
mechanisms for neutralizing antibodies to prevent virus infection, it is still unknown how they 
reach the basal epidermal layers to intervene in infection. There are two major transport 
mechanisms for IgG antibodies to reach the genital mucosa: the neonatal Fc receptor-mediated 
bidirectionally transcytoses of IgG and exudation of antibodies at the site of pathogen entry [180, 
181]. In the context of the skin, the exudation mechanism seems the most likely way, because B 
cells and IgG can enter the skin under certain circumstances [182-184]. This mechanism is also 
consistent with the fact that the PVs infect the basal epithelial layer at the traumatized epithelium 
[101, 185].  
 
It is very difficult to identify these specific epitopes of anti-L1 antibodies by the epitope 
mapping method because of limitations of the method (Fig. 4.2.9). The synthesized linear peptides 
and cyclic peptides cannot mimic the epitopes for anti-L1LONG and L1SHORT antibodies, which might 
be due to the complex of the discontinuous and conformation epitopes (discussed above). However, 
several linear epitopes were identified from sera which were mixed from five tumor-bearing 
animals. This result indicates that L1 antibodies against linear epitopes can be largely generated 
when the viral particles are massively produced. The identified ITGHPLY, DYLGMSK and 
KRSLPASRN peptide is located on the putative DE loop, FG loop and C-terminal arm, respectively, 
when MnPV L1 amino acid sequence is aligned to HPV16 L1 sequence. This result is in line with 
reports that linear epitopes are located on the VLPs surface [186, 187]. For example, HPV 2, 27 
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and 57 type-specific monoclonal antibodies against linear epitopes, were mapped to the VLPs 
hypervariable surface loop regions [188]. 
 
5.5 The interaction between L1LONG and L1SHORT 
L1LONG protein might facilitate the virus to evade the adaptive immune system in the early 
infection stage by the production of non-neutralizing antibodies. However, it is unknown how 
L1LONG can influence the appearance of these non-neutralizing antibodies and when it works as an 
antigen: either from the original virions or after virus replication from the first round of infection. 
Therefore, several hypotheses and related experiments are discussed in detail as follows: 
 
Hypothesis 1: Anti-L1LONG antibodies are raised by virions which are formed by both L1 
isoforms but with low copy numbers of L1LONG. It is known that typical capsids are composed of 
L1SHORT and L2 proteins. However, with the help of L1SHORT, a proportion of particles might be able 
to incorporate L1LONG, thus leading to a production of antibodies against the exposed N-terminal 
arm. This hypothesis can first be supported by the mass spectrometry analysis of the PsVs samples, 
where an N-terminal peptide of L1LONG was detected (Fig. 4.3.1). However, a drawback of this 
experiment is that there might be free over-expressed L1LONG proteins purified together with the 
cellular proteins after ultracentrifugation. Furthermore, the immunofluorescence staining of PsVs-
infected cells showed that L1LONG-HA and L1MIDDLE-HA fusion proteins do not take part in the 
capsid formation even with help of L1SHORT and L2 (Fig. 4.3.3). Therefore, it is very important to 
know whether the lack of HA-tag signal on the PsVs here is due to the defective capsid formation 
ability of L1LONG and L1MIDDLE or interruption of capsid assembly by the additional peptides at the 
C-terminus. According to several publications, peptide fusing to the C-terminal region, in which 
the same part was replaced, did not influence the capsid formation (VLPs still can be formed) [37, 
39, 189, 190]. Besides, the mAbs mixture staining of L1SHORT-HA fusion protein might represent 
the assembled capsid proteins, since they are neutralizing antibodies against MnPV VLPs [123]. 
There was a perfect colocalization of HA signal and mAbs mixture by detection of L1SHORT-HA 
fusion protein, which might indicate the HA-tag at the C-terminus does not interrupt the capsid 
formation of the L1 protein. However, to confirm the above assumption, capsid formation of 
L1SHORT-HA fusion protein has to be checked in the future. Besides, specific antibodies against 
L1LONG need to be produced for the detection of L1LONG on capsids as well as the expression pattern 
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in 3D raft culture or tissue sections. Overall, even though hypothesis 1 is possible, more supportive 
evidences have to be provided.  
 
Hypothesis 2: Anti-L1LONG antibodies are generated following the expression of L1LONG after 
virus infection. The absence of anti-L1SHORT antibodies in the early infection stage might be caused 
by the expression pattern which has not yet switched from long to short (see discussion in Chapter 
5.1). Apart from this reason, if both L1 proteins are expressed, the interference of L1LONG protein 
with the capsid formation process might also lead to the absence of L1SHORT seroresponses. This 
hypothesis is supported by the detection of L1LONG N-terminal peptide in PsVs extract when L1LONG 
is co-expressed with L1SHORT (Fig. 4.3.1) and further demonstrated by fewer infectious particles 
formed in the “L1L + L1S + L2” PsVs production (Fig. 4.3.4). Moreover, in addition to an 
interaction of L1LONG/L1MIDDLE and L1SHORT, co-localization was demonstrated at the nuclear rim or 
cytoplasm of transfected cells which was induced by an outward shift of the nuclear L1LONG and 
L1MIDDLE in the presence of L1SHORT (Fig. 4.3.6). Little has been reported about an interaction 
between different virus capsid protein variants. However, it was demonstrated that small molecule 
‘assembly effectors’ can interfere with capsid assembly by changing conformation, interrupting 
subunit-subunit interaction or crosslinking of protein and DNA [191, 192]. For example, peptides 
can interfere with HIV capsid substructure interaction, inhibit capsid maturation and trigger 
disassembly [191]. Small molecules are able to prevent HBV capsid assembly by altering the 
geometry of interactions between subunits or strengthening these interactions, leading to 
malformed or empty capsid, respectively [193, 194]. Therefore, L1LONG protein might also serve as 
an assembly effector that modulates capsid assembly, thus inhibiting effective capsid formation by 
L1SHORT. Overall, based on the above results, this scenario remains highly possible.  
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5.6 Conclusion and perspectives 
Mastomys coucha, which is latently infected with MnPV, is a useful preclinical model to 
investigate the role of papillomavirus-induced skin carcinogenesis. Apparently, there is immune 
tolerance after virus infection, since some animals develop cutaneous lesions such as papillomas or 
keratoacanthomas that can even progress to non-melanoma skin cancer. Considering a 
fundamental role of different L1 isoforms in virus infection, the present study shows an immune 
escape scenario, indicated by the deficiency of serum antibodies capable of neutralizing viruses in 
the early infection phase (Fig. 5.1). The L1 expression switch from a long to a short variant, the 
inability of L1LONG and L1MIDDLE to form correct capsids and interference with capsid formation 
might contribute to minimizing the exposure of viral particles to immune and epithelial cells, thus 
leading to low diversity of plasma cells secreting conformation-dependent neutralizing antibodies. 
With this strategy, viruses are able to evade the host immune system in the beginning of an 
infection, thus facilitating efficient encapsidation and productive infection at later stages of the 
viral life cycle. 
 
Figure 5.1: Schematic overview of the characterization of anti-L1LONG and L1SHORT antibodies. (A).  Antibodies 
directed against the MnPV L1LONG protein in the early infection stage are neither reactive nor protective 
against the native capsids, but possibly against the conformational epitopes on a loop formed by 41 amino 
acids at the L1LONG N-terminus. (B). Neutralizing antibodies which recognize conformational epitopes 
against the L1SHORT protein only arose during the late phase of infection. 
 
With regard to the fact that immune responses of non-neutralizing L1 antibodies are 
dominant in the MnPV early infection stage, it is also noteworthy to examine the early L1 
immune responses in unvaccinated but sexually active young women with infection of high-risk 
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HPV types, which contain alternative translation initiation codons in the L1 ORF as well. It will 
be of importance to elucidate immune escape mechanism during the history of HPV infection.  
 
Furthermore, since there were different immune responses patterns of anti-L1LONG and 
L1SHORT antibodies in the naturally infected colony, the immunogenicity of different L1 isoforms 
needs to be further investigated. The injection of plasmids exclusively expressing different L1 
isoforms and purified proteins from the baculovirus expression system will be performed with a 
tattoo gun and subcutaneous injection in virus-free animals. Such studies will be of great help to 
further understand the structure of L1LONG and L1SHORT as well as their capsid formation ability. 
Besides, future evaluation of the neutralizing capacity of anti-L1LONG and L1SHORT antibodies will be 
strengthened by passive immunization, which will be performed in virus-free animals by using 
the above generated L1 antibodies.  
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7. Appendix 
A  
aa Amino acid 
APS Ammonium persulfate 
ATG Start codon 
B  
bp  Base pairs  
BPV Bovine papillomavirus 
BSA Bovine serum albumin 
C  
CBB  Casein blocking buffer  
°C Degree Celsius 
cDNA  complementary DNA  
CDS  protein coding sequence  
CIN Cervical intraepithelial neoplasia 
cm  Centimeter  
CmPV1 Chelonia mydas papillomavirus type 1 
CMV  Cytomegalovirus  
CO2  carbon dioxide  
COPV Canine oral papillomavirus 
CPV1 Canine papillomavirus type 1 
CRPV Cottontail rabbit papillomavirus 
CsA  Cyclosporine A  
C-terminus Carboxyl-terminus 
D  
DAPI 4’, 6’-diamidino-2-phenylindol 
DCs  Dendritic cells  
ddH2O  doubly distilled water  
DMEM  Dulbecco’s modified Eagle’s medium  
DMSO  Dimethyl sulfoxide  
DNA  Deoxyribonucleic acid  
dNTP Deoxynucleotide triphosphate 
dNTPs  Deoxyribonucleotide triphosphates  
DPBS  Dublecco’s phosphate buffered saline  
DTT Dithiothreitol 
E  
E. coli  Escherichia coli  
ECL  Enhanced Chemiluminescence Substrate  
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ECM Extracellular matrix 
EDTA  Ethylenediaminetetraacetic acid  
EM Electron microscopy 
ELISA  Enzyme-linked immunosorbent assay  
F  
FCS  Fetal calf serum  
Fig. Figure 
G  
GFP  Green fluorescent protein  
GI Gastrointestinal 
GST  Glutathione S-transferase  
H  
h  Hour(s)  
H2SO4  Sulfuric acid  
HA  Hemagglutinin  
HEPES  4-(2-hydroxyethyl)-1-piperazine-ethanesulfonicacid  
HPV(s)  Human papillomavirus(es)  
HPSGs Heparin sulfate proteoglycans 
HRP  Horseradish peroxidase  
I  
IgG  Immunoglobulin G  
IgM  Immunoglobulin M  
IPTG Isopropylß -D-1-thiogalactopyranoside 
K  
Kan  Kanamycin  
kb  Kilobases  
KCl  Potassium chloride  
kDa  Kilodalton  
KH2PO4  Potassium dihydrogen phosphate  
L  
L1 Papillomavirus major capsid protein 
L2 Papillomavirus minor capsid protein 
LB  lysogeny broth  
LCs  Langerhans cells  
LT Large T antigen 
M  
M  Mol  
mA  Miliampère  
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mAbs Monoclonal antibodies 
McPV2  Mastomys coucha papillomavirus 2  
MEFs Mouse embryonic fibroblasts 
MgCl2  Magnesium chloride  
MgSO4  Magnesium sulfate  
min  Minute(s)  
mJ/cm2  Millijoule per square centimeter  
ml  Milliliter  
mM  Millimol  
MmuPV  Murine Papillomavirus  
MnPV  Mastomys natalensis papillomavirus  
mRNA  Messenger RNA  
N  
Na2HPO4  Sodium dihydrogen phosphate  
NaCl  Sodium chloride  
NaOH  Sodium hydroxide  
NLS Nuclear localization signal 
NMSC  Non-melanoma skin cancer  
nm  Nanometer  
NP-40  Nonidet P-40  
nt Nucleoride 
NT N-terminus 
N-terminus Amino-terminus 
O  
OD Optical density 
ORFs  Open reading frame(s)  
Ori  Origin of replication  
P  
PAGE  Polyacrylamide gel electrophoresis  
PBS  Phosphate-buffered saline  
PCR  Polymerase chain reaction  
PFA  Paraformaldehyde  
PML Promyelocytic leukemia protein 
PMSF Phenylmethylsulfonyl fluoride 
P/S Penicillin/Streptavidine 
PRM Parallel reaction monitoring 
PsVs Pseudovirions 
pUC  pBR322-derived vector  
PV  Papillomavirus  
PVDF  Polyvinylidene fluoride  
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PyV Polyomavirus 
R  
Rb retinoablastoma 
RNA  Ribonucleic acid  
rpm  rounds per minute  
S  
SD  Standard deviation  
SDS  Sodium dodecyl sulfate  
sec  Second(s)  
SEM  Standard error of the mean  
Sf9 Spodoptera frugiperda 9 
SOC  Super optimal broth  
SPF Specified pathogen-free 
SPP Synthetic papillomavirus particles 
SV40  Simian Virus 40  
T  
TAE  Tris acetate EDTA  
Taq  Thermus aquaticus  
TBS  Tris-buffered saline  
TBST  Tris-buffered saline + Tween20  
TEMED  Tetramethylethylenediamine  
Th1/2  T helper 1/2  
TMB  3,3',5,5'-Tetramethylbenzidine  
TN-High-5 Trichoplusia ni High-5 
URR  Upstream regulatory region  
U  
UV  Ultraviolet light  
URR upstream regulatory region 
V  
V  Volt  
VLPs  Virus-like particles  
v/v Volume per volume 
W  
WB Western blot 
  
μM Micromol 
μm Micrometer 
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